US20060224216A1 - System and method for controlling neurological disorders with spatially separated detection and therapy locations - Google Patents
System and method for controlling neurological disorders with spatially separated detection and therapy locations Download PDFInfo
- Publication number
- US20060224216A1 US20060224216A1 US11/436,189 US43618906A US2006224216A1 US 20060224216 A1 US20060224216 A1 US 20060224216A1 US 43618906 A US43618906 A US 43618906A US 2006224216 A1 US2006224216 A1 US 2006224216A1
- Authority
- US
- United States
- Prior art keywords
- brain
- stimulation
- patient
- electrodes
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0526—Head electrodes
- A61N1/0529—Electrodes for brain stimulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/369—Electroencephalography [EEG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/369—Electroencephalography [EEG]
- A61B5/372—Analysis of electroencephalograms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
- A61B5/4094—Diagnosing or monitoring seizure diseases, e.g. epilepsy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0526—Head electrodes
- A61N1/0529—Electrodes for brain stimulation
- A61N1/0534—Electrodes for deep brain stimulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36064—Epilepsy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7203—Signal processing specially adapted for physiological signals or for diagnostic purposes for noise prevention, reduction or removal
- A61B5/7217—Signal processing specially adapted for physiological signals or for diagnostic purposes for noise prevention, reduction or removal of noise originating from a therapeutic or surgical apparatus, e.g. from a pacemaker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36082—Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease
Definitions
- electrical stimulation may be particularly advantageous to apply electrical stimulation exclusively in areas distant from an epileptogenic region, as electrical stimulation of neural tissue that is especially sensitive may contribute to or initiate the hypersynchronous activity that characterizes an epileptic seizure.
- remote stimulation would serve to advantageously reduce the effects of artifacts on the epilepsy detection methods employed.
- an implantable neurostimulator will have at least two electrodes near or in contact with brain tissue. Those electrodes may be located in close proximity to each other on a single lead, or may be on separate leads in entirely different portions of the brain. Each electrode may be dedicated to a single purpose, either detection or stimulation, or may be switchable between detection and stimulation functions.
- Remote sensing and stimulation according to the invention is not necessarily constrained to being an exclusive therapy; it may be advantageously performed in concert with other treatment modalities, such as responsive drug infusion, somatosensory stimulation (including audio stimulation), or vagus nerve stimulation. Remote sensing and stimulation may also, in certain circumstances, be advantageously combined with electrical stimulation at or near the epileptogenic region, or where a seizure or its onset is first detected.
- stimulation signals remote from the epileptogenic region has several advantages. First, it is believed that such therapy will tend to avoid contributing to hypersynchronous activity in the epileptogenic region. Second, detection can be carried out at (or near) the same time stimulation is being performed, as it is less likely that the detection subsystems of the implantable neurostimulator will be affected by artifacts, specifically the stimulation signals transmitted through the brain tissue. Moreover, the ability to detect the effects of electrical stimulation on remote tissue in the patient's brain may contribute to advantages in detecting, identifying and treating seizures and other neurological events with greater precision and reliability, and with longer advance notice.
- FIG. 2 is a schematic illustration of a patient's cranium showing the implantable neurostimulator of FIG. 1 as implanted, including leads extending to the patient's brain;
- FIG. 8 is a block diagram illustrating the components of the stimulation subsystem of the implantable neurostimulator shown in FIG. 6 ;
- the neurostimulator is implanted intracranially in a patient's parietal bone 210 , in a location anterior to the lambdoidal suture 212 (see FIG. 2 ). It should be noted, however, that the placement described and illustrated herein is merely exemplary, and other locations and configurations are also possible, in the cranium or elsewhere, depending on the size and shape of the device and individual patient needs, among other factors.
- the device 110 is preferably configured to fit the contours of the patient's cranium 214 .
- the device 110 as implanted intracranially, is illustrated in greater detail in FIG. 2 .
- the device 110 is affixed in the patient's cranium 214 by way of a ferrule 216 .
- the ferrule 216 is a structural member adapted to fit into a cranial opening, attach to the cranium 214 , and retain the device 110 .
- the lead 222 is a flexible elongated member having one or more conductors. As shown, the lead 222 is coupled to the device 110 via the lead connector 220 , and is generally situated on the outer surface of the cranium 214 (and under the patient's scalp 112 ), extending between the device 110 and a burr hole 224 or other cranial opening, where the lead 222 enters the cranium 214 and is coupled to a depth electrode (see FIG. 4 ) implanted in a desired location in the patient's brain.
- a depth electrode see FIG. 4
- a neurostimulator operates in conjunction with external equipment.
- the device 110 is mostly autonomous (particularly when performing its usual sensing, detection, and stimulation capabilities), but preferably includes a selectable part-time wireless link 510 to external equipment such as a programmer 512 .
- the wireless link 510 is established by moving a wand (or other apparatus) having communication capabilities and coupled to the programmer 512 into range of the device 110 .
- the programmer 512 can then be used to manually control the operation of the device 110 , as well as to transmit information to or receive information from the device 110 .
- the stimulation generator 812 is coupled to a multiplexer 814 , which is controllable to select the appropriate types of stimulation and pass them along to a stimulation signal generator 816 .
- the multiplexer 814 allows different stimulation parameters to be selectively applied to the different electrodes 612 - 618 , either sequentially or substantially simultaneously.
- the stimulation signal generator 816 receives commands and data from the stimulation generator 812 , and generates electrical stimulation signals having the desired characteristics that are properly time-correlated and associated with the correct electrodes, and receives power from a controllable voltage multiplier 818 to facilitate the application of a proper voltage and current to the desired neurological tissue.
- Commands to start and stop electrical stimulation to the appropriate set of brain electrodes are then sent from the programmer 512 to be stored in the implantable device 110 and activated in response to a command from the physician.
- Stimulation is performed to induce epileptiform activity that may include after-discharges from an epileptogenic region of the patient's brain. Such after-discharges typically are similar to natural epileptiform activity. It should be noted that inducing after-discharges may require empirical testing of various stimulation parameters programmed by the programmer 512 into the implantable device 110 ; this procedure may require substantial physician interaction.
Abstract
A system and method for controlling epilepsy and other neurological disorders by providing electrical stimulation to a patient's brain in response to detected neurological conditions. An implantable device includes a stimulation subsystem coupled to a stimulation electrode to provide responsive electrical brain stimulation in response to an event detected via an on-board processor's analysis of data received from a detection subsystem coupled to a detection electrode located in a different portion of the patient's brain.
Description
- This is a continuation of U.S. patent application Ser. No. 09/724,805, filed on Nov. 28, 2000 and issued as U.S. Pat. No. 6,597,954, which is a continuation-in-part of U.S. patent application Ser. No. 09/543,264, filed on Apr. 5, 2000; a continuation-in-part of U.S. patent application No. 09/373,676, filed on Aug. 13, 1999 and now issued as U.S. Pat. No. 6,230,049; and a continuation-in-part of U.S. patent application Ser. No. 09/628,977, filed on Aug. 2, 2000 and now issued as U.S. Pat. No. 6,360,122, which was a continuation of U.S. patent application Ser. No. 09/450,303, filed on Nov. 29, 1999 and now issued as U.S. Pat. No. 6,128,538, which was in turn a continuation of U.S. patent application Ser. No. 08/957,869, filed on Oct. 27, 1997 and now issued as U.S. Pat. No. 6,016,449.
- The invention relates to systems and methods for treating neurological disorders, and more particularly to a system and method employing an electronic device for sensing and detecting neurological dysfunction, specifically neuronal activity characteristic of epileptic seizures, in one region of a patient's brain, and applying treatment in response thereto in another region of the patient's brain.
- Epilepsy, a neurological disorder characterized by the occurrence of seizures (specifically episodic impairment or loss of consciousness, abnormal motor phenomena, psychic or sensory disturbances, or the perturbation of the autonomic nervous system), is debilitating to a great number of people. It is believed that as many as two to four million Americans may suffer from various forms of epilepsy. Research has found that its prevalence may be even greater worldwide, particularly in less economically developed nations, suggesting that the worldwide figure for epilepsy sufferers may be in excess of one hundred million.
- Because epilepsy is characterized by seizures, its sufferers are frequently limited in the kinds of activities they may participate in. Epilepsy can prevent people from driving, working, or otherwise participating in much of what society has to offer. Some epilepsy sufferers have serious seizures so frequently that they are effectively incapacitated.
- Furthermore, epilepsy is often progressive and can be associated with degenerative disorders and conditions. Over time, epileptic seizures often become more frequent and more serious, and in particularly severe cases, are likely to lead to deterioration of other brain functions (including cognitive function) as well as physical impairments.
- The current state of the art in treating neurological disorders, particularly epilepsy, typically involves drug therapy and surgery. The first approach is usually drug therapy. A number of drugs are approved and available for treating epilepsy, such as sodium valproate, phenobarbital/primidone, ethosuximide, gabapentin, phenytoin, and carbamazepine, as well as a number of others. Unfortunately, those drugs typically have serious side effects, especially toxicity, and it is extremely important in most cases to maintain a precise therapeutic serum level to avoid breakthrough seizures (if the dosage is too low) or toxic effects (if the dosage is too high). The need for patient discipline is high, especially when a patient's drug regimen causes unpleasant side effects the patient may wish to avoid.
- Moreover, while many patients respond well to drug therapy alone, a significant number (at least 20-30%) do not. For those patients, surgery is presently the best-established and most viable alternative course of treatment.
- Currently practiced surgical approaches include radical surgical resection such as hemispherectomy, corticectomy, lobectomy and partial lobectomy, and less-radical lesionectomy, transection, and stereotactic ablation. Besides being less than fully successful, these surgical approaches generally have a high risk of complications, and can often result in damage to eloquent (i.e., functionally important) brain regions and the consequent long-term impairment of various cognitive and other neurological functions. Furthermore, for a variety of reasons, such surgical treatments are contraindicated in a substantial number of patients. And unfortunately, even after radical brain surgery, many epilepsy patients are still not seizure-free.
- Electrical stimulation is an emerging therapy for treating epilepsy. However, currently approved and available electrical stimulation devices apply continuous electrical stimulation to neural tissue surrounding or near implanted electrodes, and do not perform any detection—they are not responsive to relevant neurological conditions.
- The NeuroCybernetic Prosthesis (NCP) from Cyberonics, for example, applies continuous electrical stimulation to the patient's vagus nerve. This approach has been found to reduce seizures by about 50% in about 50% of patients. Unfortunately, a much greater reduction in the incidence of seizures is needed to provide clinical benefit. The Activa device from Medtronic is a pectorally implanted continuous deep brain stimulator intended primarily to treat Parkinson's disease. In operation, it supplies a continuous electrical pulse stream to a selected deep brain structure where an electrode has been implanted.
- A typical epilepsy patient experiences episodic attacks or seizures, which are generally defined as periods of abnormal neurological activity. As is traditional in the art, such periods shall be referred to herein as “ictal” (though it should be noted that “ictal” can refer to neurological phenomena other than epileptic seizures).
- Known work on detection and treatment of epilepsy via electrical stimulation has focused on a region of the brain frequently referred to as an epileptic (or epileptogenic) focus, particularly in patients suffering from partial epilepsy (the most common form of adult-onset epilepsy). In at least some partial epilepsy sufferers, it is the area where hypersynchronous activity consistently begins; it typically spreads outward, and into other regions of the brain, from there. The characteristics of an epileptic seizure onset are different from patient to patient, but are frequently consistent from seizure to seizure within a single patient. Although seizures in a partial epilepsy sufferer frequently begin in the same region of the brain, they may secondarily generalize quickly to cover a significant portion of the brain. Patients with primary generalized epilepsy may not have any specific identifiable seizure origin.
- Unfortunately, continuous stimulation of deep brain structures for the treatment of epilepsy has not met with consistent success. To be effective in terminating seizures, it has traditionally been believed that epilepsy stimulation should be performed near the focus of the epileptogenic region. The focus is often in the neocortex, where continuous stimulation may cause significant neurological deficit with clinical symptoms including loss of speech, sensory disorders, or involuntary motion. Accordingly, research has been directed toward automatic responsive epilepsy treatment at or near the focus, based on a detection of imminent seizure.
- Recent research, however, indicates that the concept of a single epileptic focus does not necessarily accurately reflect the origins of partial epilepsy, at least in humans. See J. Engel, Jr., Intracerebral Recordings: Organization of the Human Epileptic Region, J. Clin. Neurophysiol. 1993; 10(1): 90-98. The human brain is a complex system, and although an anomalous signal may first be detected via known methods at a particular location or region, that does not necessarily imply that area is the true epileptogenic origin of an epileptic seizure. Nor is the region where abnormal signals are first identified necessarily the location where it is most effective to treat a seizure or its precursor. In fact, it is possible to have multiple locations in a single patient's brain that all act as epileptic foci. And in generalized seizures, abnormal EEG signals can be found throughout a patient's brain practically simultaneously.
- Most prior work on the detection and responsive treatment of seizures via electrical stimulation has focused on analysis of electroencephalogram (EEG) and electrocorticogram (ECoG) waveforms. In general, EEG signals represent aggregate neuronal activity potentials detectable via electrodes applied to a patient's scalp, and ECoGs use internal electrodes near the surface of the brain. ECoG signals, deep-brain counterparts to EEG signals, are also detectable via electrodes implanted under the dura mater, and usually within the patient's brain. Unless the context clearly and expressly indicates otherwise, the term “EEG” shall be used generically herein to refer to both EEG and ECoG signals.
- Much of the work on detection has focused on the use of time-domain analysis of EEG signals. See, e.g., J. Gotman, Automatic seizure detection: improvements and evaluation, Electroencephalogr. Clin. Neurophysiol. 1990; 76(4): 317-24. In a typical time-domain detection system, EEG signals are received by one or more implanted electrodes and then processed by a control module, which then is capable of performing an action (intervention, warning, recording, etc.) when an abnormal event is detected.
- In the Gotman system, EEG waveforms are filtered and decomposed into “features” representing characteristics of interest in the waveforms. One such feature is characterized by the regular occurrence (i.e., density) of half-waves exceeding a threshold amplitude occurring in a specified frequency band between approximately 3 Hz and 20 Hz, especially in comparison to background (non-ictal) activity. When such half-waves are detected, the onset of a seizure is identified. For related approaches, see also H. Qu and J. Gotman, A seizure warning system for long term epilepsy monitoring, Neurology 1995; 45: 2250-4; and H. Qu and J. Gotman, A Patient-Specific Algorithm for the Detection of Seizure Onset in Long-Tern EEG Monitoring: Possible Use as a Warning Device, IEEE Trans. Biomed. Eng. 1997; 44(2): 115-22.
- A more computationally demanding approach is to transform EEG signals into the frequency domain for rigorous spectrum analysis. See, e.g., U.S. Pat. No. 5,995,868 to Dorfmeister et al., which analyzes the power spectral density of EEG signals in comparison to background characteristics. Although this approach is generally believed to achieve good results, for the most part, its computational expense renders it less than optimal for use in long-term implanted epilepsy monitor and treatment devices. With current technology, the battery life in an implantable device computationally capable of performing the Dorfmeister method would be too short for it to be feasible.
- Also representing an alternative and more complex approach is U.S. Pat. No. 5,857,978 to Hively et al., in which various non-linear and statistical characteristics of EEG signals are analyzed to identify the onset of ictal activity. Once more, the calculation of statistically relevant characteristics is not believed to be feasible in an implantable device.
- U.S. Pat. No. 6,016,449 to Fischell, et al., entitled “System for Treatment of Neurological Disorders,” which is hereby incorporated by reference as though set forth in full herein, describes an implantable seizure detection and treatment system. In the Fischell system, various detection methods are possible, all of which essentially rely upon the analysis (either in the time domain or the frequency domain) of processed EEG signals. Fischell's controller is preferably implanted intracranially, but other approaches are also possible, including the use of an external controller. When a seizure is detected, the Fischell system applies responsive electrical stimulation to terminate the seizure, a capability that will be discussed in further detail below.
- All of these approaches provide useful information, and in some cases may provide sufficient information for accurate detection and prediction of most imminent epileptic seizures.
- Accordingly, as has been previously suggested, it is possible to treat and terminate seizures by applying electrical stimulation to the brain. See, e.g., U.S. Pat. No. 6,016,449 to Fischell et al., and H. R. Wagner, et al., Suppression of cortical epileptiform activity by generalized and localized ECoG desynchronization, Electroencephalogr. Clin. Neurophysiol. 1975; 39(5): 499-506. It should be noted, however, that the epilepsy detection methods described above rely, at least in part, on the continuous analysis of EEG signals. To the extent responsive electrical stimulation is applied in response to a detection of epileptiform activity, artifacts of the stimulation received by the epileptiform activity detector may be significantly disruptive of the detection algorithms. A potential solution to this problem is to blank the sensing amplifiers used to receive EEG signals during and for a period after the application of electrical stimulation, but this will lead to a loss of data during the blanking period.
- To recapitulate somewhat, in general, partial epilepsy is a much more complex phenomenon than traditionally thought. It is believed to be advantageous to provide therapeutic electrical stimulation in a number of brain regions involved in a patient's epilepsy, but known approaches do not do this in any meaningful way. Given the neural organization of the brain, in a given patient it may be more effective to stimulate pathways associated with epileptogenic focus, rather than the focus itself, to disrupt or block the epileptiform activity to prevent the occurrence of a clinical seizure. It is anticipated that stimulation from contralateral structures, particularly when the focus is hippocampal, may be the preferred method of treating some types of spontaneously occurring epileptiform activity. In addition, it may be particularly advantageous to apply electrical stimulation exclusively in areas distant from an epileptogenic region, as electrical stimulation of neural tissue that is especially sensitive may contribute to or initiate the hypersynchronous activity that characterizes an epileptic seizure. And furthermore, remote stimulation would serve to advantageously reduce the effects of artifacts on the epilepsy detection methods employed.
- Accordingly, a system and method according to the invention for treating a neurological disorder such as epilepsy includes an implantable electronic device capable of detecting seizure activity and its precursors, as well as providing responsive electrical stimulation to brain tissue.
- The treatment methods of the present invention can be accomplished with a number of different approaches. In a typical embodiment, an implantable neurostimulator will have at least two electrodes near or in contact with brain tissue. Those electrodes may be located in close proximity to each other on a single lead, or may be on separate leads in entirely different portions of the brain. Each electrode may be dedicated to a single purpose, either detection or stimulation, or may be switchable between detection and stimulation functions.
- Sensing and stimulating electrodes according to the invention are situated in different regions of the patient's brain. The regions may be physically or functionally distinct, but at least one set of sensing and stimulating electrodes should be remote from each other to facilitate the advantages and avoid the disadvantages set forth above.
- Several potential regions of interest for remote sensing and stimulation have been identified. As used herein, “remote sensing and stimulation” means sensing in one area of the brain and stimulating in another area. In particular, several of these regions are described in greater detail in the Engel article referenced above, and will be further characterized in the detailed description below.
- Remote sensing and stimulation according to the invention is not necessarily constrained to being an exclusive therapy; it may be advantageously performed in concert with other treatment modalities, such as responsive drug infusion, somatosensory stimulation (including audio stimulation), or vagus nerve stimulation. Remote sensing and stimulation may also, in certain circumstances, be advantageously combined with electrical stimulation at or near the epileptogenic region, or where a seizure or its onset is first detected.
- In any event, by way of the present invention, neurological signals are received by at least one electrode and analyzed by the implantable neurostimulator to identify an epileptic seizure or, preferably, its onset in advance of any clinical symptoms, or even just the increased likelihood that a seizure may occur. Responsive electrical stimulation treatment is applied elsewhere in the patient's brain.
- The application of stimulation signals remote from the epileptogenic region has several advantages. First, it is believed that such therapy will tend to avoid contributing to hypersynchronous activity in the epileptogenic region. Second, detection can be carried out at (or near) the same time stimulation is being performed, as it is less likely that the detection subsystems of the implantable neurostimulator will be affected by artifacts, specifically the stimulation signals transmitted through the brain tissue. Moreover, the ability to detect the effects of electrical stimulation on remote tissue in the patient's brain may contribute to advantages in detecting, identifying and treating seizures and other neurological events with greater precision and reliability, and with longer advance notice.
- These and other objects, features, and advantages of the invention will become apparent from the detailed description below and the accompanying drawings, in which:
-
FIG. 1 is a schematic illustration of a patient's head showing the placement of an implantable neurostimulator according to an embodiment of the invention; -
FIG. 2 is a schematic illustration of a patient's cranium showing the implantable neurostimulator ofFIG. 1 as implanted, including leads extending to the patient's brain; -
FIG. 3 is a schematic illustration of several regions in a single hemisphere of a patient's brain, including the hippocampus; -
FIG. 4 is a schematic bilateral sectional view of a patient's brain, illustrating the placement of electrodes in two corresponding contralateral regions illustrated inFIG. 3 in one embodiment of the invention; -
FIG. 5 is a block diagram illustrating context in which an implantable neurostimulator according to the invention is implanted and operated; -
FIG. 6 is a block diagram illustrating the major subsystems of an implantable neurostimulator according to the invention; -
FIG. 7 is a block diagram illustrating the components of the detection subsystem of the implantable neurostimulator shown inFIG. 6 ; -
FIG. 8 is a block diagram illustrating the components of the stimulation subsystem of the implantable neurostimulator shown inFIG. 6 ; -
FIG. 9 is a schematic illustration of a deep brain lead having four electrodes for use in a system or method according to the invention; -
FIG. 10 is a schematic illustration of a subdural brain surface lead having four electrodes for use in a system or method according to the invention; and -
FIG. 11 is a schematic representation of a top view of a patient's head, illustrating the implantable neurostimulator connected to two deep brain leads, each with four electrodes. - The invention is described below, with reference to detailed illustrative embodiments. It will be apparent that a system according to the invention may be embodied in a wide variety of forms. Consequently, the specific structural and functional details disclosed herein are representative and do not limit the scope of the invention.
-
FIG. 1 depicts an intracranially implanteddevice 110 according to the invention, which in one embodiment is a small self-contained responsive neurostimulator. As the term is used herein, a responsive neurostimulator is a device capable of detecting ictal activity (or other neurological events) and providing electrical stimulation to neural tissue in response to that activity, where the electrical stimulation is specifically intended to terminate the ictal activity or treat the neurological event. - In the disclosed embodiment, the neurostimulator is implanted intracranially in a patient's
parietal bone 210, in a location anterior to the lambdoidal suture 212 (seeFIG. 2 ). It should be noted, however, that the placement described and illustrated herein is merely exemplary, and other locations and configurations are also possible, in the cranium or elsewhere, depending on the size and shape of the device and individual patient needs, among other factors. Thedevice 110 is preferably configured to fit the contours of the patient'scranium 214. In an alternative embodiment, thedevice 110 is implanted under the patient'sscalp 112 but external to the cranium; it is expected, however, that this configuration would generally cause an undesirable protrusion in the patient's scalp where the device is located. In yet another alternative embodiment, when it is not possible to implant the device intracranially, it may be implanted pectorally (not shown), with leads extending through the patient's neck and between the patient's cranium and scalp, as necessary. - It should be recognized that the embodiment of the
device 110 described and illustrated herein is preferably a responsive neurostimulator for detecting and treating epilepsy by detecting seizure precursors (or the seizure) and preventing and/or terminating epileptic seizures. However, a primary function of a device according to the invention is to detect any increased likelihood of the brain developing a seizure by identifying trends and conditions suggesting that increased likelihood, taking actions to prevent the seizure from occurring or terminate the seizure once it has begun, and using neurological conditions (such as the characteristics of EEG signals received by the device 110) to specify or adjust the actions taken. - The
device 110, as implanted intracranially, is illustrated in greater detail inFIG. 2 . Thedevice 110 is affixed in the patient'scranium 214 by way of aferrule 216. Theferrule 216 is a structural member adapted to fit into a cranial opening, attach to thecranium 214, and retain thedevice 110. - To implant the
device 110, a craniotomy is performed in the parietal bone anterior to thelambdoidal suture 212 to define anopening 218 slightly larger than thedevice 110. Theferrule 216 is inserted into theopening 218 and affixed to thecranium 214, ensuring a tight and secure fit. Thedevice 110 is then inserted into and affixed to theferrule 216. - As shown in
FIG. 2 , thedevice 110 includes alead connector 220 adapted to receive one or more electrical leads, such as afirst lead 222. Thelead connector 220 acts to physically secure thelead 222 to thedevice 110, and facilitates electrical connection between a conductor in thelead 222 coupling an electrode to circuitry within thedevice 110. Thelead connector 220 accomplishes this in a substantially fluid-tight environment with biocompatible materials. - The
lead 222, as illustrated, and other leads for use in a system or method according to the invention, is a flexible elongated member having one or more conductors. As shown, thelead 222 is coupled to thedevice 110 via thelead connector 220, and is generally situated on the outer surface of the cranium 214 (and under the patient's scalp 112), extending between thedevice 110 and aburr hole 224 or other cranial opening, where thelead 222 enters thecranium 214 and is coupled to a depth electrode (seeFIG. 4 ) implanted in a desired location in the patient's brain. If the length of thelead 222 is substantially greater than the distance between thedevice 110 and theburr hole 224, any excess may be urged into a coil configuration under thescalp 112. As described in U.S. Pat. No. 6,006,124 to Fischell, et al., theburr hole 224 is sealed after implantation to prevent further movement of thelead 222; in an embodiment of the invention, a burr hole cover apparatus is affixed to thecranium 214 at least partially within theburr hole 224 to provide this functionality. - The
device 110 includes a durableouter housing 226 fabricated from a biocompatible material. Titanium, which is light, extremely strong, and biocompatible, is used in analogous devices, such as cardiac pacemakers, and would serve advantageously in this context. As thedevice 110 is self-contained, thehousing 226 encloses a battery and any electronic circuitry necessary or desirable to provide the functionality described herein, as well as any other features. As will be described in further detail below, a telemetry coil may be provided outside of the housing 226 (and potentially integrated with the lead connector 220) to facilitate communication between thedevice 110 and external devices. - The neurostimulator configuration described herein and illustrated in
FIG. 2 provides several advantages over alternative designs. First, the self-contained nature of the neurostimulator substantially decreases the need for access to thedevice 110, allowing the patient to participate in normal life activities. Its small size and intracranial placement causes a minimum of cosmetic disfigurement. Thedevice 110 will fit in an opening in the patient's cranium, under the patient's scalp, with little noticeable protrusion or bulge. Theferrule 216 used for implantation allows the craniotomy to be performed and fit verified without the possibility of breaking thedevice 110, and also provides protection against thedevice 110 being pushed into the brain under external pressure or impact. A further advantage is that theferrule 216 receives any cranial bone growth, so at explant, thedevice 110 can be replaced without removing any bone screws—only the fasteners retaining thedevice 110 in theferrule 216 need be manipulated. - As set forth above, the invention is directed to the detection of abnormal EEG signals in one portion of a patient's brain and applying responsive therapy in a different portion of the patient's brain. An exemplary coronal section of a
human brain 310, illustrating several brain anatomical details of interest, is shown inFIG. 3 , which primarily shows a temporal lobe of a single hemisphere. As briefly explained above, and as described in further detail below, the limbic system is implicated in some cases of epilepsy. The normal human limbic system is responsible for processing and regulating emotions, feelings, and moods.FIG. 3 illustrates several structures of the human brain and limbic system, in particular thehippocampus 312, theparahippocampal gyrus 314, thedentate gyrus 316, thehypothalamus 318, thethalamus 320, and theamygdala 322. It is believed that some or all of these structures, as well as the functional pathways involved in communication among these structures and others, may be implicated in epilepsy. For example, see C. L. Wilson, “Neurophysiology of Epileptic Limbic Pathways in Intact Human Temporal Lobe,” in P. Kotagal et al., ed., The Epilepsies: Etiologies and Prevention, San Diego: Academic Press 1999, 171-9, which suggests that a perforant pathway (indicated by arepresentative arrow 324 that is not meant to indicate the actual path of neuronal communication) between the entorhinal cortex (of which theparahippocampal gyrus 314 forms a part) and the anterior portion of thehippocampus 312 is subject to hypersynchronous neuronal activity in a substantial number of epilepsy sufferers. - The
coronal brain section 310 ofFIG. 3 represents a functional illustration of several structures of the limbic system. As can be appreciated, there is a complex interrelationship among the illustrated structures (in particular thehippocampus 312 and the parahippocampal gyrus 314) and many of the other structures of the limbic system; it should be noted that the gross generalization of the limbic system pathways presented herein is not a complete description of the functionality of the brain, the limbic system, or any portion thereof. It is intended to be illustrative of some diagnosis, measurement, detection, and treatment options facilitated by the invention. - An electrode configuration capable of measuring EEG signals in a patient's
hippocampus 312 and delivering electrical stimulation to acontralateral hippocampus 412 is illustrated inFIG. 4 in the context of a bilateralcoronal brain section 410. - A
first lead 414 is illustrated extending from outside the patient'sbrain 416 into thehippocampus 312. The illustrativefirst lead 414 has fourdistal electrodes 418, 420, 422, and 424. Three of the electrodes 418-422 are located in thehippocampus 312, while the most distal electrode 424 is in thedentate gyrus 316. Asecond lead 426 also extends from outside the patient'sbrain 416 and into thecontralateral hippocampus 412; its fourelectrodes dentate gyrus 436. - In one embodiment of the present invention, the
first lead 414 will be used for sensing and detection, and thesecond lead 426 will provide responsive electrical stimulation. The individual electrodes (of the electrodes 418-424) used on thefirst lead 414 will be selected by the physician based on clinical judgment perhaps as a result of mapping and testing, depending at least in part on which electrodes provide effective sensing and discrimination of epileptiform activity. Likewise, the individual electrodes (of the electrodes 428-434) used for stimulation on thesecond lead 426 will be selected by the physician depending on which electrodes are expected to provide effective results in terminating seizure activity; some testing (as described below) may be required. - It will be appreciated that the electrode configuration illustrated in
FIG. 4 is also capable of performing several alternate modes of detection and therapy. As thefirst lead 414 includes a plurality of distal electrodes (in the illustrated embodiment, four distal electrodes), it is possible to sense or stimulate, or both, from any one or more of those electrodes. Similarly, thesecond lead 426 also includes a plurality of distal electrodes, each individually selectable for sensing or stimulation. Moreover, as illustrated, both thefirst lead 414 and thesecond lead 426 extend into the patient'sdentate gyri hippocampus 312, thecontralateral hippocampus 412, thedentate gyrus 316, and the contralateraldentate gyrus 436. Of course, with alternative lead configurations and approaches, numerous other combinations are also possible. - It should be noted that although electrode implantation in and around the hippocampus (and the contralateral hippocampus) is illustrated and described in some detail above, that implementation of the invention is merely illustrative, and is intended to provide an example of how the invention might advantageously be employed. In particular, as stated above, several other regions of interest for remote sensing and stimulation have been identified. Several of these regions are described in greater detail in the Engel article referenced above.
- An epileptogenic lesion refers to a specific pathological cause of partial epilepsy, such as a stroke, tumor, sclerosis of brain tissue, or trauma, though the specific condition may not be readily apparent. An epileptogenic region (or ictal onset zone) is a theoretical (and difficult-to-bound) region of brain tissue necessary and sufficient to give rise to seizure activity. A focal functional deficit is an area of be brain that gives rise to abnormal non-epileptic or epileptic EEG activity. A spike focus is another term for the epileptic focus concept described above, though there is not necessarily a discrete focal generator of spike activity—EEG spikes may be distributed throughout the brain. An irritative zone is a brain region that generates interictal spikes, but is not necessary for seizure initiation (as the epileptogenic region is). As will be described in detail below, the hippocampus is particularly implicated in many cases of epilepsy, and it may be advantageous to sense or stimulate in the hippocampus (or other structures of the limbic system) regardless of the origin of abnormal EEG activity. Other locations in the temporal lobe, and elsewhere in the brain (including corresponding contralateral locations, even when seizures fail to generalize to the contralateral hemisphere), also present themselves as candidates for treatment in accordance with the invention. The possibilities are too numerous to set forth herein, but should be apparent to a neurosurgical or neurological practitioner having skill and experience in treating epilepsy.
- According to Engel, the epileptogenic region, focal functional deficit, epileptogenic lesion, and spike focus need not be overlapping or even contiguous within the brain tissue. Consequently, as stated above, human partial epilepsy is a complex phenomenon, and the approach set forth herein to sense and stimulate in remote locations may provide distinct advantages over simply sensing and stimulating in the vicinity of a focus. And with regard to generalized epilepsy (either primary or secondary), there is not necessarily any single point or region of interest in the brain, and successful treatment demands an alternative approach.
- As stated above, and as illustrated in
FIG. 5 , a neurostimulator according to the invention operates in conjunction with external equipment. Thedevice 110 is mostly autonomous (particularly when performing its usual sensing, detection, and stimulation capabilities), but preferably includes a selectable part-time wireless link 510 to external equipment such as aprogrammer 512. In the disclosed embodiment of the invention, thewireless link 510 is established by moving a wand (or other apparatus) having communication capabilities and coupled to theprogrammer 512 into range of thedevice 110. Theprogrammer 512 can then be used to manually control the operation of thedevice 110, as well as to transmit information to or receive information from thedevice 110. Several specific capabilities and operations performed by theprogrammer 512 in conjunction with thedevice 110 will be described in further detail below. - The
programmer 512 is capable of performing a number of advantageous operations in connection with the invention. In particular, theprogrammer 512 is able to specify and set variable parameters in thedevice 110 to adapt the function of thedevice 110 to meet the patient's needs, download or receive data (including but not limited to stored EEG waveforms, parameters, or logs of actions taken) from thedevice 110 to theprogrammer 512, upload or transmit program code and other information from theprogrammer 512 to thedevice 110, or command thedevice 110 to perform specific actions or change modes as desired by a physician operating theprogrammer 512. To facilitate these functions, theprogrammer 512 is adapted to receivephysician input 514 and providephysician output 516; data is transmitted between theprogrammer 512 and thedevice 110 over thewireless link 510. - The
programmer 512 is coupled via acommunication link 518 to anetwork 520 such as the Internet. This allows any information downloaded from thedevice 110, as well as any program code or other information to be uploaded to thedevice 110, to be stored in a database at one or more data repository locations (which may include various servers and network-connected programmers like the programmer 512). This would allow a patient (and the patient's physician) to have access to important data, including past treatment information and software updates, essentially anywhere in the world that there is a programmer (like the programmer 512) and a network connection. - An overall block diagram of the
device 110 used for measurement, detection, and treatment according to the invention is illustrated inFIG. 6 . Inside thehousing 226 of thedevice 110 are several subsystems making up acontrol module 610. Thecontrol module 610 is capable of being coupled to a plurality ofelectrodes control module 610 via a lead that is analogous or identical to thelead 222 ofFIG. 2 ) for sensing and stimulation. In the illustrated embodiment, the coupling is accomplished through the lead connector 220 (FIG. 2 ). Although four electrodes are shown inFIG. 6 for simplicity of explanation, it should be recognized that any number is possible; in fact, it is possible to employ an embodiment of the invention that uses a single lead with at least two electrodes, or two leads each with a single electrode (or with a second electrode provided by a conductive exterior portion of thehousing 226 in one embodiment), although bipolar sensing between two closely spaced electrodes on a lead is preferred to minimize common mode signals including noise. - The electrodes 612-618 are connected to an
electrode interface 620. Preferably, the electrode interface is capable of selecting each electrode as required for sensing and/or stimulation; accordingly the electrode interface is coupled to adetection subsystem 622 and astimulation subsystem 624. The electrode interface is also may provide any other features, capabilities, or aspects, including but not limited to amplification, isolation, and charge-balancing functions, that are required for a proper interface with neurological tissue and not provided by any other subsystem of thedevice 110. - The
detection subsystem 622 includes anEEG analyzer function 626. TheEEG analyzer function 626 is adapted to receive EEG signals from the electrodes 612-618, through theelectrode interface 620, and to process those EEG signals to identify neurological activity indicative of a seizure or a precursor to a seizure. One way to implement such EEG analysis functionality is disclosed in detail in U.S. Pat. No. 6,016,449 to Fischell et al., incorporated by reference above. The detection subsystem may optionally also contain further sensing and detection capabilities, including but not limited to parameters derived from other physiological conditions (such as electrophysiological parameters, temperature, blood pressure, etc.). - The
stimulation subsystem 624 is capable of applying electrical stimulation to neurological tissue through the electrodes 612-618. This can be accomplished in any of a number of different manners. For example, it may be advantageous in some circumstances to provide stimulation in the form of a substantially continuous stream of pulses. Preferably, therapeutic stimulation is provided in response to abnormal events detected by theEEG analyzer function 626 of thedetection subsystem 622. As illustrated inFIG. 6 , thestimulation subsystem 624 and theEEG analyzer function 626 are connected; this facilitates the ability ofstimulation subsystem 624 to provide responsive stimulation as well as an ability of thedetection subsystem 622 to blank the amplifiers while stimulation is being performed to minimize stimulation artifacts. It is contemplated that the parameters of the stimulation signal (e.g., frequency, duration, waveform) provided by thestimulation subsystem 624 would be specified by other subsystems in thecontrol module 610, as will be described in further detail below. - Also in the
control module 610 is amemory subsystem 630 and a central processing unit (CPU) 632, which can take the form of a microcontroller. The memory subsystem is coupled to the detection subsystem 622 (e.g., for receiving and storing data representative of sensed EEG signals and evoked responses), the stimulation subsystem 624 (e.g., for providing stimulation waveform parameters to the stimulation subsystem), and theCPU 632, which can control the operation of thememory subsystem 630. In addition to thememory subsystem 630, theCPU 632 is also connected to thedetection subsystem 622 and thestimulation subsystem 624 for direct control of those subsystems. - Also provided in the
control module 610, and coupled to thememory subsystem 630 and theCPU 632, is acommunication subsystem 634. Thecommunication subsystem 634 enables communication between the device 110 (FIG. 1 ) and the outside world, particularly the external programmer 512 (FIG. 5 ). As set forth above, the disclosed embodiment of thecommunication subsystem 634 includes a telemetry coil (which may be situated outside of the housing 226) enabling transmission and reception of signals, to or from an external apparatus, via inductive coupling. Alternative embodiments of thecommunication subsystem 634 could use an antenna for an RF link or an audio transducer for an audio link. - Rounding out the subsystems in the
control module 610 are a power supply 636 and a clock supply 638. The power supply 636 supplies the voltages and currents necessary for each of the other subsystems. The clock supply 638 supplies substantially all of the other subsystems with any clock and timing signals necessary for their operation. - It should be observed that while the
memory subsystem 630 is illustrated inFIG. 6 as a separate functional subsystem, the other subsystems may also require various amounts of memory to perform the functions described above and others. Furthermore, while thecontrol module 610 is preferably a single physical unit contained within a single physical enclosure, namely the housing 226 (FIG. 2 ), it may comprise a plurality of spatially separate units each performing a subset of the capabilities described above. Also, it should be noted that the various functions and capabilities of the subsystems described above may be performed by electronic hardware, computer software (or firmware), or a combination thereof. The division of work between theCPU 632 and the other functional subsystems may also vary—the functional distinctions illustrated inFIG. 6 may not reflect the integration of functions in a real-world system or method according to the invention. -
FIG. 7 illustrates details of the detection subsystem 622 (FIG. 6 ). Inputs from the electrodes 612-618 are on the left, and connections to other subsystems are on the right. - Signals received from the electrodes 612-618 (as routed through the electrode interface 620) are received in an
electrode selector 710. Theelectrode selector 710 allows the device to select which electrodes (of the electrodes 612-618) should be routed to which individual channels of thedetection subsystem 622, based on control received through acontrol interface 718 from thememory subsystem 630 or the CPU 632 (FIG. 6 ). Theelectrode selector 710 provides signals corresponding to each selected electrode (of the electrodes 612-618) to a bank ofdifferential amplifiers 712, which are gain-matched and adapted to amplify the input signals to a level capable of being processed by a system or method according to the invention. The bank ofdifferential amplifiers 712 includes a plurality of channels; each channel receives a pair of electrode signals from theelectrode selector 710 and amplifies the difference in potential between them to derive an analog input signal representative of the bipolar signal between two selected electrodes. - The bank of
amplifiers 712 transmits the amplified analog input signals to a bank of analog-to-digital converters (ADCs) 714, which generates a number of digital signals corresponding to the analog input signals. These digital signals are passed to amultiplexer 716, which interleaves the digital signals. The multiplexed input signal is then fed from themultiplexer 716 to asignal processor 720. - Although
FIG. 7 illustrates themultiplexer 716 placed between the bank ofADCs 714 and thesignal processor 720, it should be noted that a multiplexing function can be performed between theelectrode selector 710 and the bank of differential amplifiers 712 (which, in this embodiment, would be a single amplifier), or between thedifferential amplifiers 712 and the ADCs 714 (in this embodiment, a single ADC). There are tradeoffs inherent in any of these configurations that would be known to a practitioner of ordinary skill in the arts of electronics design and signal processing. - The
signal processor 720 is preferably a special-purpose digital signal processor (DSP) adapted for use with the invention, or in an alternative embodiment, may comprise a programmable general-purpose DSP. In the disclosed embodiment, the signal processor has its own scratchpad memory area 722 used for local storage of data and program variables when the signal processing is being performed. In either case, the signal processor performs suitable measurement and detection methods described generally above. Any results from such methods, as well as any digitized signals intended for storage transmission to external equipment, are passed to various other subsystems of thecontrol module 610, including thememory subsystem 630 and the CPU 632 (FIG. 6 ) through a data interface 724. - The various functions and capabilities of the
stimulation subsystem 624 are illustrated in greater detail inFIG. 8 . Consistent withFIG. 6 , inputs to thestimulation subsystem 624 are shown on the right, and outputs are on the left. - Referring initially to the input side of
FIG. 6 , thestimulation subsystem 624 includes acontrol interface 810, which receives commands, data, and other information from theCPU 632, thememory subsystem 630, and thedetection subsystem 622. Thecontrol interface 810 uses the received commands, data, and other information to control astimulation generator 812. Thestimulation generator 812 is adapted to provide electrical stimulation signals appropriate for application to neurological tissue to terminate a present or predicted undesired neurological event, especially an epileptic seizure (or its precursor). As set forth above, thestimulation generator 812 is typically activated in response to conditions detected by thedetection subsystem 622, but may also provide some substantially continuous stimulation. - The
stimulation generator 812 is coupled to amultiplexer 814, which is controllable to select the appropriate types of stimulation and pass them along to astimulation signal generator 816. In a presently preferred embodiment, themultiplexer 814 allows different stimulation parameters to be selectively applied to the different electrodes 612-618, either sequentially or substantially simultaneously. Thestimulation signal generator 816 receives commands and data from thestimulation generator 812, and generates electrical stimulation signals having the desired characteristics that are properly time-correlated and associated with the correct electrodes, and receives power from acontrollable voltage multiplier 818 to facilitate the application of a proper voltage and current to the desired neurological tissue. Thevoltage multiplier 818 is capable of creating relatively high voltages from a battery power source, which typically has a very low voltage; circuits to accomplish this function are well known in the art of electronics design. Thestimulation signal generator 816 has a plurality of outputs, which in the disclosed embodiment are coupled to the electrode interface 620 (FIG. 6 ). In various embodiments of the invention, thestimulation signal generator 816 can perform signal isolation, multiplexing, and queuing functions if theelectrode interface 620 does not perform such functions. - It should be recognized that while various functional blocks are illustrated in
FIG. 8 , not all of them might be present in an operative embodiment of the invention. Furthermore, as with the overall block diagram ofFIG. 6 , the functional distinctions illustrated inFIG. 8 , which are presented as separate functions for clarity and understandability herein, might not be meaningful distinctions in an implementation of the invention. - For an initial detection and mapping procedure, a system according to the invention typically would be employed as follows.
- First, brain electrodes (including surface electrodes, depth electrodes, or a combination thereof, as described below with reference to
FIGS. 9-10 ) are implanted by a neurosurgeon in areas believed to be relevant. As set forth above, those regions may be any of a number of structurally or functionally distinct brain areas, such as the structures of the limbic system, epileptogenic regions, focal functional deficit regions, irritative zones, focal areas, and others. EEG data would then be collected by thecontrol module 610 of theimplantable device 110 and transmitted to theprogrammer 512 over thewireless link 510. If it is impractical to employ theimplantable device 110 for this purpose (e.g., if the necessary capabilities cannot be implemented in the required small form factor), an external apparatus having the appropriate functionality may be substituted for theimplantable device 110 on a short-term (and typically inpatient) basis. After sufficient epileptiform activity has been collected by theprogrammer 512, a physician would use the stored EEG data, as displayed by theprogrammer 512, to select appropriate electrodes for sensing and stimulation by theimplantable device 110. In one embodiment of the invention, the appropriate stimulation electrodes are those in the region showing the highest indication of epileptiform activity, but as set forth above in connection with the present invention, stimulation in other regions may be advantageous. - The stimulation parameters (e.g., pulse width, voltage, current, frequency, etc.) would then be selected on the
programmer 512 and transmitted to thecontrol module 610 via thewireless link 510. Various commands to start and stop stimulation on specific electrodes would also be transmitted from theprogrammer 512 to thecontrol module 610. - Finally, the stimulation effects on the patient would be noted by the physician as in a standard brain mapping procedure. This standard brain mapping procedure typically uses electrodes near the site of an epileptic focus to map brain functions as a precursor to surgical excision of the epileptogenic region, but in connection with the present invention, the analogous procedure serves as an indication of where sensing and stimulation might advantageously be performed.
- Thereafter, for an epileptiform activity detection and control procedure in connection with the present invention, the system would be used as follows. It will be appreciated that the
programmer 512 remains in contact with thecontrol module 610 of theimplantable device 110 for much of this process. - First, brain electrodes (including surface electrodes, depth electrodes, or a combination thereof) are implanted by a neurosurgeon. EEG data is then collected by the
programmer 512 from EEG signals received, amplified, and stored by the control module 610 (as described above) and transmitted to theprogrammer 512. - Again, after sufficient epileptiform activity has been collected by the
programmer 512, a physician would use the stored EEG data, as displayed by theprogrammer 512, to select an appropriate set of brain electrodes for long-term sensing and stimulation by the implantable device. As illustrated in U.S. patent application Ser. No. 09/543,264 to Pless, entitled “A Neurostimulator Involving Stimulation Strategies and Process for Using It,” which is hereby incorporated by reference as though set forth in full herein, the analysis performed by the physician (and automatically by the programmer 512) on the stored EEG data would be used to set parameters for epileptiform activity detection algorithms employed by theimplantable device 110 according to the invention. - Commands to start and stop electrical stimulation to the appropriate set of brain electrodes are then sent from the
programmer 512 to be stored in theimplantable device 110 and activated in response to a command from the physician. Stimulation is performed to induce epileptiform activity that may include after-discharges from an epileptogenic region of the patient's brain. Such after-discharges typically are similar to natural epileptiform activity. It should be noted that inducing after-discharges may require empirical testing of various stimulation parameters programmed by theprogrammer 512 into theimplantable device 110; this procedure may require substantial physician interaction. - When induced epileptiform activity occurs, the physician uses the
programmer 512 to initiate stimulation that is substantially identical to the stimulation that caused the after-discharge activity described above. If subsequent measurements through the electrodes (e.g., those on thefirst lead 414 ofFIG. 4 ) show that the epileptiform activity has not terminated, the physician adjusts the stimulation parameters on theprogrammer 512 and causes thedevice 110 to re-apply stimulation until the epileptiform activity is stopped. Typically, the choice of electrodes, stimulation voltage, and/or pulse width would be adjusted until induced epileptiform activity is promptly stopped. It should be noted that if the epileptiform activity cannot be stopped, then the patient may not be a candidate for treatment via electrical stimulation, or the stimulation electrodes (e.g., the electrodes on thesecond lead 426 ofFIG. 4 ) may not be appropriately placed. - It should be noted that an automated system could be used to detect natural epileptiform activity and automatically respond, thereby testing the stimulation parameters, rather than inducing artificial epileptiform activity and responding manually, as described above. If a patient experiences seizures frequently, such as every few hours, this may be a practical approach. On the other hand, if the patient has seizures infrequently, such as a small number per week, it most likely would not be practical to proceed in this manner.
- After successful stimulation parameters are identified, all such parameters, including the selected stimulation electrodes, are retained in the
programmer 512 and stored in thedevice 110. If thedevice 110 has not yet been implanted, or if a different apparatus is appropriate (e.g., the substitution of an implantable device for an external device used for the test procedure set forth above), the parameters are stored in the appropriate device, which is then tested for efficacy in the automatic detection and termination of seizure activity. If any adjustments are necessary, they are made by the physician, and thedevice 110 is implanted (along with any necessary electrodes for detection and stimulation). - For further details on the processes set forth above, see U.S. patent application Ser. No. 09/373,676 to Fischell et al., entitled “Integrated System For EEG Monitoring and Electrical Stimulation with a Multiplicity of Electrodes,” which is hereby incorporated by reference as though set forth in full herein.
- One significant aspect of this invention is the potential use of multiple brain electrodes to provide therapy. One embodiment of a device especially suitable for practicing certain variations of the inventive process is shown in
FIG. 9 . Intracerebral depth leads, which often incorporate line arrays of electrodes (as shown inFIG. 9 ), are useful for recording from or stimulating deep cerebral structures such as the amygdala, hippocampus, cingulate and orbital-frontal regions, which deep cerebral structures are characteristically involved in many medically refractory partial epilepsies, as described above in connection withFIG. 3 . Adeep brain lead 910 includes multipledistal electrodes - Brain electrodes can also include electrodes placed elsewhere under the patient's scalp near or within the brain.
FIG. 10 depicts arepresentative electrode assembly 1010 placed under the dura mater on the brain. There are fourelectrodes insulated electrode backing 1020 that prevents current flow back to the dura mater. Current flow back to the dura matter is often uncomfortable for the patient. Although only four electrodes are illustrated inFIG. 10 , it should be noted that an array of surface of electrodes usable in conjunction with the present invention and placed on the surface of the patient's brain may include more than one hundred separate electrodes. - The electrodes 1012-1018 are electrically connected to the neurostimulator (not shown) by conductors enclosed in the lead body 1022. An exemplary epileptogenic region 1024 is outlined for clarity, but is generally not visually apparent. To achieve spatial heterogeneity of electrical stimulation to most optimally desynchronize neuronal activity, the strategies described in this patent may be applied to all the electrodes 1012-1018 together or separately. It is particularly advantageous to apply separate burst parameters being applied to each of the
electrodes - It should be recognized, of course, that the strategies and parameters applicable to treating an individual patient's neurological disorder may vary from case to case. For further information on the selection of advantageous parameters, see U.S. patent application Ser. No. 09/543,264, incorporated by reference above.
-
FIG. 11 schematically illustrates an exemplary configuration of theimplantable system 1110 for the treatment of neurological disorders as it would be generally situated under the scalp of ahuman head 1112 and implanted intracranially. The illustrated embodiment of thesystem 1110 has acontrol module 1114, twoleads lead connector 1120 on thecontrol module 1114 to a plurality ofdistal electrodes 1122. It is envisioned that thecontrol module 1114 is permanently implanted into the patient's cranium in a location where the bone is fairly thick. In an alternative embodiment, it is also envisioned that thecontrol module 1114 could be located in the trunk of the patient's body like a heart pacemaker with the connecting wires being run under the patient's skin. Depending on the application, theelectrodes 1122 would be placed under the cranium and above the dura mater (i.e., placed epidurally) or placed deep into the brain. The connecting leads 1116 and 1118 are run from thecontrol module 1114, underneath the patient's scalp, throughburr holes 1123 to the electrodes placed beneath the patient's cranium. AlthoughFIG. 11 illustrates shows only fouractive electrodes 1122 on each of the connecting leads 1116 and 1118, it should be noted that more than four active electrodes with connecting wires may be used with and by the present invention. In the illustrated embodiment, ahousing 1124 for thecontrol module 1114, or a separate electrode 1126 (having a connecting lead 1128) could be considered a common or indifferent electrode. - As described above, the
leads electrodes 1122 to the detection subsystem 622 (FIG. 6 ). Theelectrodes 1122 can also be energized by thestimulation subsystem 624 via theleads electrodes 112 illustrated and described herein are connected to both thedetection subsystem 622 and thestimulation subsystem 624 by way of theelectrode interface 620, it should be apparent that a separate set of electrodes and associated wires could be used with each subsystem. Furthermore, it is envisioned that in certain circumstances, any one, several or all of theelectrodes 1122 could be electrically connected (i.e., shorted) to thecommon electrode electrode interface 620 or thestimulation subsystem 624. - The general operation of the
system 1110 ofFIG. 11 for detecting and treating a neurological event such as an epileptic seizure would be as follows. Further information on detection methods and systems adaptable to employ the systems and methods of the current invention are set forth in detail in U.S. Pat. No. 6,016,449 to Fischell et al., incorporated by reference above. - First, the
detection subsystem 622 continuously processes the EEG signals carried by theleads electrodes 1122. When an event is detected, thedetection subsystem 622 notifies the processor 628 (FIG. 6 ) that an event has occurred. - The
processor 628 then triggers thestimulation subsystem 624 to electrically stimulate the patient's brain (or release medication, or other appropriate action) in order to stop the neurological event using any one, several or all of theelectrodes 1122, as set forth above. Thestimulation subsystem 624 also causes a signal to be sent to thedetection subsystem 622 to disable event detection during stimulation to avoid any undesired input into thedetection subsystem 622. As noted above, in an embodiment of the invention, the need for such blanking may be reduced or eliminated when the detection and stimulation sites are sufficiently separated. - The
central processor 628 also preferably causes EEG signals and event-related data received from thedetection subsystem 622 to be stored over a time period extending from X minutes before the event to Y minutes after the event, for storage and later analysis by the patient's physician. The value of X and Y may be set from as little as 0.1 minutes to as long as 30 minutes. - The typical stimulation signals generated by the stimulation subsystem should be biphasic (that is with equal energy positive and negative of ground) with a typical frequency of between 30 and 200 Hz, although frequencies of between 0.1 and 1000 Hz may be effective. It is also envisioned that stimulation signals having substantial DC voltage components might be used. If frequencies above 30 Hz are used, the signal generators could be capacitively coupled to the
leads - It should be observed that while the foregoing detailed description of various embodiments of the present invention is set forth in some detail, the invention is not limited to those details and an implantable neurostimulator or neurological disorder detection device made according to the invention can differ from the disclosed embodiments in numerous ways. In particular, it will be appreciated that embodiments of the present invention may be employed in many different applications to detect anomalous neurological characteristics in at least one portion of a patient's brain. It will be appreciated that the functions disclosed herein as being performed by hardware and software, respectively, may be performed differently in an alternative embodiment. It should be further noted that functional distinctions are made above for purposes of explanation and clarity; structural distinctions in a system or method according to the invention may not be drawn along the same boundaries. Hence, the appropriate scope hereof is deemed to be in accordance with the claims as set forth below.
Claims (9)
1. A system for providing therapy to a patient's brain in response to a detected event, the system comprising:
a therapy delivery mechanism coupled to at least one therapy delivery site in the patient's brain;
a detection subsystem coupled to at least one detection electrode in the patient's brain, wherein the detection subsystem is operative to receive and process a detected signal received by the detection electrode; and
a processor operative to identify a detected event in the detected signal and to cause the therapy delivery mechanism to apply a dose of therapy in response thereto;
wherein the detection electrode is situated in a first brain region and the at least one therapy delivery site is situated in at least one different second brain region.
2. The method of claim 1 , wherein the therapy delivery mechanism comprises a stimulation subsystem.
3. The system of claim 1 , wherein the at least one therapy delivery site comprises a plurality of locations in the patient's brain.
4. The system of claim 3 , wherein the therapy delivery mechanism is adapted to deliver a plurality of therapies to the plurality of locations.
5. The system of claim 4 , wherein the plurality of therapies comprises a plurality of bursts of electrical stimulation, at least one burst for each location of the plurality of locations.
6. The system of claim 5 , wherein the bursts of electrical stimulation have different stimulation parameters.
7. The system of claim 5 , wherein the bursts of electrical stimulation have equivalent stimulation parameters.
8. A method for responsively treating a neurological disorder in a patient with therapy applied to the patient's brain, the method comprising the steps of:
receiving a signal representative of a neurological event with a detection electrode implanted in a first region of the patient's brain;
transmitting the signal to a detection subsystem, wherein the detection subsystem is adapted to receive and process the signal received by the detection electrode;
identifying a neurological event representative of the neurological disorder with a processor coupled to the detection subsystem;
in response to the neurological event, causing a therapy delivery mechanism to apply a dose of a therapy to at least one therapy delivery site in at least one second region of the patient's brain.
9. The method of claim 8 , wherein the at least one therapy delivery site comprises a plurality of locations in the patient's brain, and wherein the step of causing the therapy delivery mechanism to apply a dose of a therapy comprises applying a plurality of therapies to the plurality of locations, at least one therapy for each of the plurality of locations.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/436,189 US20060224216A1 (en) | 1997-10-27 | 2006-05-16 | System and method for controlling neurological disorders with spatially separated detection and therapy locations |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/957,869 US6016449A (en) | 1997-10-27 | 1997-10-27 | System for treatment of neurological disorders |
US09/373,676 US6230049B1 (en) | 1999-08-13 | 1999-08-13 | Integrated system for EEG monitoring and electrical stimulation with a multiplicity of electrodes |
US09/450,303 US6128538A (en) | 1997-10-27 | 1999-11-29 | Means and method for the treatment of neurological disorders |
US09/543,264 US6944501B1 (en) | 2000-04-05 | 2000-04-05 | Neurostimulator involving stimulation strategies and process for using it |
US09/628,977 US6360122B1 (en) | 1997-10-27 | 2000-08-02 | Data recording methods for an implantable device |
US09/724,805 US6597954B1 (en) | 1997-10-27 | 2000-11-28 | System and method for controlling epileptic seizures with spatially separated detection and stimulation electrodes |
US10/625,829 US20040153129A1 (en) | 1997-10-27 | 2003-07-22 | System and method for controlling neurological disorders with spatially separated detection and therapy locations |
US11/436,189 US20060224216A1 (en) | 1997-10-27 | 2006-05-16 | System and method for controlling neurological disorders with spatially separated detection and therapy locations |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/625,829 Continuation US20040153129A1 (en) | 1997-10-27 | 2003-07-22 | System and method for controlling neurological disorders with spatially separated detection and therapy locations |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060224216A1 true US20060224216A1 (en) | 2006-10-05 |
Family
ID=27541333
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/724,805 Expired - Lifetime US6597954B1 (en) | 1997-10-27 | 2000-11-28 | System and method for controlling epileptic seizures with spatially separated detection and stimulation electrodes |
US10/625,829 Abandoned US20040153129A1 (en) | 1997-10-27 | 2003-07-22 | System and method for controlling neurological disorders with spatially separated detection and therapy locations |
US11/436,189 Abandoned US20060224216A1 (en) | 1997-10-27 | 2006-05-16 | System and method for controlling neurological disorders with spatially separated detection and therapy locations |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/724,805 Expired - Lifetime US6597954B1 (en) | 1997-10-27 | 2000-11-28 | System and method for controlling epileptic seizures with spatially separated detection and stimulation electrodes |
US10/625,829 Abandoned US20040153129A1 (en) | 1997-10-27 | 2003-07-22 | System and method for controlling neurological disorders with spatially separated detection and therapy locations |
Country Status (1)
Country | Link |
---|---|
US (3) | US6597954B1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070073150A1 (en) * | 2005-09-29 | 2007-03-29 | University Of Chicago | Surface acoustic wave probe implant for predicting epileptic seizures |
US20100023100A1 (en) * | 2008-07-24 | 2010-01-28 | Boston Scientific Neoromodulation Corporation | Cam lock burr hole plug for securing stimulation lead |
US20100023020A1 (en) * | 2008-07-24 | 2010-01-28 | Boston Scientific Neuromodulation Corporation | Cam lock burr hole plug for securing retainer/plug base |
US20100228075A1 (en) * | 2009-03-06 | 2010-09-09 | Neuralieve | Method and Apparatus to Record and Analyze TMS Treatments and Results |
US20110021885A1 (en) * | 2007-05-03 | 2011-01-27 | Cornell Research Foundation, Inc. | Subdural electro-optical sensor |
US10232169B2 (en) | 2015-07-23 | 2019-03-19 | Boston Scientific Neuromodulation Corporation | Burr hole plugs for electrical stimulation systems and methods of making and using |
US11013913B2 (en) | 2018-03-16 | 2021-05-25 | Boston Scientific Neuromodulation Corporation | Kits and methods for securing a burr hole plugs for stimulation systems |
US11058870B2 (en) | 2018-03-09 | 2021-07-13 | Boston Scientific Neuromodulation Corporation | Burr hole plugs for electrical stimulation systems and methods of making and using |
US11103716B2 (en) | 2017-11-13 | 2021-08-31 | Boston Scientific Neuromodulation Corporation | Systems and methods for making and using a low-profile control module for an electrical stimulation system |
US11273283B2 (en) | 2017-12-31 | 2022-03-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
US11452839B2 (en) | 2018-09-14 | 2022-09-27 | Neuroenhancement Lab, LLC | System and method of improving sleep |
US11497914B2 (en) | 2018-01-16 | 2022-11-15 | Boston Scientific Neuromodulation Corporation | Systems and methods for making and using an electrical stimulation system with a case-neutral battery |
US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
US11723579B2 (en) | 2017-09-19 | 2023-08-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
Families Citing this family (299)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020169485A1 (en) | 1995-10-16 | 2002-11-14 | Neuropace, Inc. | Differential neurostimulation therapy driven by physiological context |
US6944501B1 (en) * | 2000-04-05 | 2005-09-13 | Neurospace, Inc. | Neurostimulator involving stimulation strategies and process for using it |
US6597954B1 (en) * | 1997-10-27 | 2003-07-22 | Neuropace, Inc. | System and method for controlling epileptic seizures with spatially separated detection and stimulation electrodes |
US7747325B2 (en) | 1998-08-05 | 2010-06-29 | Neurovista Corporation | Systems and methods for monitoring a patient's neurological disease state |
US8762065B2 (en) | 1998-08-05 | 2014-06-24 | Cyberonics, Inc. | Closed-loop feedback-driven neuromodulation |
US7209787B2 (en) | 1998-08-05 | 2007-04-24 | Bioneuronics Corporation | Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease |
US7974696B1 (en) | 1998-08-05 | 2011-07-05 | Dilorenzo Biomedical, Llc | Closed-loop autonomic neuromodulation for optimal control of neurological and metabolic disease |
US9320900B2 (en) | 1998-08-05 | 2016-04-26 | Cyberonics, Inc. | Methods and systems for determining subject-specific parameters for a neuromodulation therapy |
US9042988B2 (en) | 1998-08-05 | 2015-05-26 | Cyberonics, Inc. | Closed-loop vagus nerve stimulation |
US9415222B2 (en) | 1998-08-05 | 2016-08-16 | Cyberonics, Inc. | Monitoring an epilepsy disease state with a supervisory module |
US9375573B2 (en) | 1998-08-05 | 2016-06-28 | Cyberonics, Inc. | Systems and methods for monitoring a patient's neurological disease state |
US7231254B2 (en) * | 1998-08-05 | 2007-06-12 | Bioneuronics Corporation | Closed-loop feedback-driven neuromodulation |
US6650943B1 (en) | 2000-04-07 | 2003-11-18 | Advanced Bionics Corporation | Fully implantable neurostimulator for cavernous nerve stimulation as a therapy for erectile dysfunction and other sexual dysfunction |
CN1440256A (en) * | 2000-05-08 | 2003-09-03 | 布雷恩斯盖特有限公司 | Method and apparatus for stimulating sphenopalatine ganglion to modify properties of BBB and cerebral blood flow |
US7146209B2 (en) * | 2000-05-08 | 2006-12-05 | Brainsgate, Ltd. | Stimulation for treating eye pathologies |
US7640062B2 (en) | 2000-05-08 | 2009-12-29 | Brainsgate Ltd. | Methods and systems for management of alzheimer's disease |
US7117033B2 (en) * | 2000-05-08 | 2006-10-03 | Brainsgate, Ltd. | Stimulation for acute conditions |
US8046076B2 (en) | 2000-06-20 | 2011-10-25 | Boston Scientific Neuromodulation Corporation | Treatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion |
WO2001097906A2 (en) * | 2000-06-20 | 2001-12-27 | Advanced Bionics Corporation | Apparatus for treatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion |
US7672730B2 (en) * | 2001-03-08 | 2010-03-02 | Advanced Neuromodulation Systems, Inc. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US7305268B2 (en) | 2000-07-13 | 2007-12-04 | Northstar Neurscience, Inc. | Systems and methods for automatically optimizing stimulus parameters and electrode configurations for neuro-stimulators |
US7831305B2 (en) | 2001-10-15 | 2010-11-09 | Advanced Neuromodulation Systems, Inc. | Neural stimulation system and method responsive to collateral neural activity |
US7024247B2 (en) * | 2001-10-15 | 2006-04-04 | Northstar Neuroscience, Inc. | Systems and methods for reducing the likelihood of inducing collateral neural activity during neural stimulation threshold test procedures |
US7236831B2 (en) * | 2000-07-13 | 2007-06-26 | Northstar Neuroscience, Inc. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US7756584B2 (en) | 2000-07-13 | 2010-07-13 | Advanced Neuromodulation Systems, Inc. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US20050240229A1 (en) * | 2001-04-26 | 2005-10-27 | Whitehurst Tood K | Methods and systems for stimulation as a therapy for erectile dysfunction |
US6885895B1 (en) | 2001-04-26 | 2005-04-26 | Advanced Bionics Corporation | Methods and systems for electrical and/or drug stimulation as a therapy for erectile dysfunction |
US6810285B2 (en) * | 2001-06-28 | 2004-10-26 | Neuropace, Inc. | Seizure sensing and detection using an implantable device |
IL145700A0 (en) * | 2001-09-30 | 2002-06-30 | Younis Imad | Electrode system for neural applications |
US7221981B2 (en) | 2002-03-28 | 2007-05-22 | Northstar Neuroscience, Inc. | Electrode geometries for efficient neural stimulation |
US7684859B2 (en) | 2002-04-25 | 2010-03-23 | Brainsgate Ltd. | Stimulation of the OTIC ganglion for treating medical conditions |
US20040015205A1 (en) * | 2002-06-20 | 2004-01-22 | Whitehurst Todd K. | Implantable microstimulators with programmable multielectrode configuration and uses thereof |
US7860570B2 (en) | 2002-06-20 | 2010-12-28 | Boston Scientific Neuromodulation Corporation | Implantable microstimulators and methods for unidirectional propagation of action potentials |
US7203548B2 (en) | 2002-06-20 | 2007-04-10 | Advanced Bionics Corporation | Cavernous nerve stimulation via unidirectional propagation of action potentials |
US7292890B2 (en) | 2002-06-20 | 2007-11-06 | Advanced Bionics Corporation | Vagus nerve stimulation via unidirectional propagation of action potentials |
US6934580B1 (en) * | 2002-07-20 | 2005-08-23 | Flint Hills Scientific, L.L.C. | Stimulation methodologies and apparatus for control of brain states |
US6717804B1 (en) * | 2002-09-30 | 2004-04-06 | Hewlett-Packard Development Company, L.P. | Light-emitting lock device control element and electronic device including the same |
US7933646B2 (en) * | 2002-10-15 | 2011-04-26 | Medtronic, Inc. | Clustering of recorded patient neurological activity to determine length of a neurological event |
AU2003278006A1 (en) * | 2002-10-15 | 2004-05-04 | Creo Inc. | Automated information management system and methods |
EP1565102A4 (en) * | 2002-10-15 | 2008-05-28 | Medtronic Inc | Synchronization and calibration of clocks for a medical device and calibrated clock |
AU2003301370A1 (en) * | 2002-10-15 | 2004-05-04 | Medtronic Inc. | Multi-modal operation of a medical device system |
EP1558130A4 (en) * | 2002-10-15 | 2009-01-28 | Medtronic Inc | Screening techniques for management of a nervous system disorder |
US7149572B2 (en) * | 2002-10-15 | 2006-12-12 | Medtronic, Inc. | Phase shifting of neurological signals in a medical device system |
WO2004034997A2 (en) * | 2002-10-15 | 2004-04-29 | Medtronic Inc. | Medical device system with relaying module for treatment of nervous system disorders |
US7715919B2 (en) * | 2002-10-15 | 2010-05-11 | Medtronic, Inc. | Control of treatment therapy during start-up and during operation of a medical device system |
WO2004036372A2 (en) * | 2002-10-15 | 2004-04-29 | Medtronic Inc. | Scoring of sensed neurological signals for use with a medical device system |
EP1558128B1 (en) * | 2002-10-15 | 2014-04-30 | Medtronic, Inc. | Signal quality monitoring and control for a medical device system |
US20040138647A1 (en) * | 2002-10-15 | 2004-07-15 | Medtronic, Inc. | Cycle mode providing redundant back-up to ensure termination of treatment therapy in a medical device system |
AU2003285895A1 (en) * | 2002-10-15 | 2004-05-04 | Medtronic Inc. | Measuring a neurological event using clustering |
US8543214B2 (en) * | 2002-10-15 | 2013-09-24 | Medtronic, Inc. | Configuring and testing treatment therapy parameters for a medical device system |
ATE542566T1 (en) * | 2002-10-15 | 2012-02-15 | Medtronic Inc | CHANNEL SELECTIVE COVERING FOR A MEDICAL SYSTEM |
WO2004041352A1 (en) * | 2002-10-31 | 2004-05-21 | Medtronic, Inc. | Distributed system for neurostimulation therapy programming |
US7236830B2 (en) | 2002-12-10 | 2007-06-26 | Northstar Neuroscience, Inc. | Systems and methods for enhancing or optimizing neural stimulation therapy for treating symptoms of Parkinson's disease and/or other movement disorders |
JP2006515999A (en) | 2002-11-14 | 2006-06-15 | ブレインズゲート リミティド | Surgical tools and techniques for stimulation |
US7561919B2 (en) * | 2002-11-14 | 2009-07-14 | Brainsgate Ltd. | SPG stimulation via the greater palatine canal |
US20050075680A1 (en) | 2003-04-18 | 2005-04-07 | Lowry David Warren | Methods and systems for intracranial neurostimulation and/or sensing |
US7596408B2 (en) * | 2002-12-09 | 2009-09-29 | Medtronic, Inc. | Implantable medical device with anti-infection agent |
AU2003297735A1 (en) | 2002-12-09 | 2004-06-30 | Medtronic, Inc. | Modular implantable medical device |
AU2003298493A1 (en) * | 2002-12-18 | 2004-07-09 | Matsushita Electric Industrial Co., Ltd. | Exposing apparatus and image forming apparatus using organic electroluminescence element |
US7269455B2 (en) * | 2003-02-26 | 2007-09-11 | Pineda Jaime A | Method and system for predicting and preventing seizures |
US8118722B2 (en) | 2003-03-07 | 2012-02-21 | Neuronetics, Inc. | Reducing discomfort caused by electrical stimulation |
US7153256B2 (en) | 2003-03-07 | 2006-12-26 | Neuronetics, Inc. | Reducing discomfort caused by electrical stimulation |
US7317947B2 (en) * | 2003-05-16 | 2008-01-08 | Medtronic, Inc. | Headset recharger for cranially implantable medical devices |
US7263401B2 (en) * | 2003-05-16 | 2007-08-28 | Medtronic, Inc. | Implantable medical device with a nonhermetic battery |
US20050004637A1 (en) * | 2003-05-16 | 2005-01-06 | Ruchika Singhal | Explantation of implantable medical device |
CA2432810A1 (en) * | 2003-06-19 | 2004-12-19 | Andres M. Lozano | Method of treating depression, mood disorders and anxiety disorders by brian infusion |
WO2005011805A2 (en) | 2003-08-01 | 2005-02-10 | Northstar Neuroscience, Inc. | Apparatus and methods for applying neural stimulation to a patient |
US7187967B2 (en) * | 2003-09-30 | 2007-03-06 | Neural Signals, Inc. | Apparatus and method for detecting neural signals and using neural signals to drive external functions |
US9278208B1 (en) | 2003-10-20 | 2016-03-08 | University Of Central Florida Research Foundation, Inc. | Spatial-temporal deep brain stimulation methods and systems |
US7383090B2 (en) * | 2003-10-20 | 2008-06-03 | Greatbatch Ltd. | Connection for a coiled lead to an electrical contact for an implantable medical device |
US8024049B1 (en) * | 2003-10-20 | 2011-09-20 | University Of Central Florida Research Foundation, Inc. | Spatial-temporal deep brain stimulation methods and systems |
US20050143589A1 (en) * | 2003-11-09 | 2005-06-30 | Donoghue John P. | Calibration systems and methods for neural interface devices |
US7104947B2 (en) * | 2003-11-17 | 2006-09-12 | Neuronetics, Inc. | Determining stimulation levels for transcranial magnetic stimulation |
WO2005051479A2 (en) * | 2003-11-20 | 2005-06-09 | Advanced Neuromodulation Systems, Inc. | Electrical stimulation system and method for treating tinnitus |
US9050469B1 (en) | 2003-11-26 | 2015-06-09 | Flint Hills Scientific, Llc | Method and system for logging quantitative seizure information and assessing efficacy of therapy using cardiac signals |
WO2005058135A2 (en) * | 2003-12-12 | 2005-06-30 | Washington University | Electrocorticography telemitter |
US7120486B2 (en) | 2003-12-12 | 2006-10-10 | Washington University | Brain computer interface |
US20050131735A1 (en) * | 2003-12-15 | 2005-06-16 | Degeorge Michael P. | Computerized system and method for identifying and storing time zone information in a healthcare environment |
US7783353B2 (en) | 2003-12-24 | 2010-08-24 | Cardiac Pacemakers, Inc. | Automatic neural stimulation modulation based on activity and circadian rhythm |
CA2454184A1 (en) * | 2003-12-23 | 2005-06-23 | Andres M. Lozano | Method and apparatus for treating neurological disorders by electrical stimulation of the brain |
US8200331B2 (en) * | 2004-11-04 | 2012-06-12 | Cardiac Pacemakers, Inc. | System and method for filtering neural stimulation |
US20050149132A1 (en) | 2003-12-24 | 2005-07-07 | Imad Libbus | Automatic baroreflex modulation based on cardiac activity |
US7651459B2 (en) * | 2004-01-06 | 2010-01-26 | Neuronetics, Inc. | Method and apparatus for coil positioning for TMS studies |
US8467875B2 (en) | 2004-02-12 | 2013-06-18 | Medtronic, Inc. | Stimulation of dorsal genital nerves to treat urologic dysfunctions |
US20050182456A1 (en) * | 2004-02-18 | 2005-08-18 | Ziobro John F. | Automated cortical mapping |
US8010189B2 (en) * | 2004-02-20 | 2011-08-30 | Brainsgate Ltd. | SPG stimulation for treating complications of subarachnoid hemorrhage |
US9233245B2 (en) | 2004-02-20 | 2016-01-12 | Brainsgate Ltd. | SPG stimulation |
US8055347B2 (en) | 2005-08-19 | 2011-11-08 | Brainsgate Ltd. | Stimulation for treating brain events and other conditions |
US8055348B2 (en) | 2004-03-16 | 2011-11-08 | Medtronic, Inc. | Detecting sleep to evaluate therapy |
US7717848B2 (en) | 2004-03-16 | 2010-05-18 | Medtronic, Inc. | Collecting sleep quality information via a medical device |
US8725244B2 (en) | 2004-03-16 | 2014-05-13 | Medtronic, Inc. | Determination of sleep quality for neurological disorders |
US7366572B2 (en) | 2004-03-16 | 2008-04-29 | Medtronic, Inc. | Controlling therapy based on sleep quality |
US8177702B2 (en) | 2004-04-15 | 2012-05-15 | Neuronetics, Inc. | Method and apparatus for determining the proximity of a TMS coil to a subject's head |
US8019413B2 (en) | 2007-03-19 | 2011-09-13 | The Invention Science Fund I, Llc | Lumen-traveling biological interface device and method of use |
US7998060B2 (en) | 2004-04-19 | 2011-08-16 | The Invention Science Fund I, Llc | Lumen-traveling delivery device |
US8337482B2 (en) | 2004-04-19 | 2012-12-25 | The Invention Science Fund I, Llc | System for perfusion management |
US8353896B2 (en) | 2004-04-19 | 2013-01-15 | The Invention Science Fund I, Llc | Controllable release nasal system |
US9801527B2 (en) | 2004-04-19 | 2017-10-31 | Gearbox, Llc | Lumen-traveling biological interface device |
US7857767B2 (en) | 2004-04-19 | 2010-12-28 | Invention Science Fund I, Llc | Lumen-traveling device |
US8092549B2 (en) | 2004-09-24 | 2012-01-10 | The Invention Science Fund I, Llc | Ciliated stent-like-system |
US8361013B2 (en) | 2004-04-19 | 2013-01-29 | The Invention Science Fund I, Llc | Telescoping perfusion management system |
US7850676B2 (en) | 2004-04-19 | 2010-12-14 | The Invention Science Fund I, Llc | System with a reservoir for perfusion management |
US9011329B2 (en) | 2004-04-19 | 2015-04-21 | Searete Llc | Lumenally-active device |
US7596399B2 (en) | 2004-04-29 | 2009-09-29 | Medtronic, Inc | Implantation of implantable medical device |
US7313442B2 (en) * | 2004-04-30 | 2007-12-25 | Advanced Neuromodulation Systems, Inc. | Method of treating mood disorders and/or anxiety disorders by brain stimulation |
US20050245984A1 (en) | 2004-04-30 | 2005-11-03 | Medtronic, Inc. | Implantable medical device with lubricious material |
US9205255B2 (en) | 2004-06-10 | 2015-12-08 | Medtronic Urinary Solutions, Inc. | Implantable pulse generator systems and methods for providing functional and/or therapeutic stimulation of muscles and/or nerves and/or central nervous system tissue |
US8195304B2 (en) * | 2004-06-10 | 2012-06-05 | Medtronic Urinary Solutions, Inc. | Implantable systems and methods for acquisition and processing of electrical signals |
US7761167B2 (en) | 2004-06-10 | 2010-07-20 | Medtronic Urinary Solutions, Inc. | Systems and methods for clinician control of stimulation systems |
US8165692B2 (en) | 2004-06-10 | 2012-04-24 | Medtronic Urinary Solutions, Inc. | Implantable pulse generator power management |
WO2005123185A1 (en) * | 2004-06-10 | 2005-12-29 | Ndi Medical, Llc | Implantable system for processing myoelectric signals |
US9308382B2 (en) | 2004-06-10 | 2016-04-12 | Medtronic Urinary Solutions, Inc. | Implantable pulse generator systems and methods for providing functional and/or therapeutic stimulation of muscles and/or nerves and/or central nervous system tissue |
WO2006009771A1 (en) * | 2004-06-18 | 2006-01-26 | Neuronetrix, Inc. | Evoked response testing system for neurological disorders |
AU2005275209B2 (en) | 2004-07-15 | 2010-06-24 | Advanced Neuromodulation Systems, Inc. | Systems and methods for enhancing or affecting neural stimulation efficiency and/or efficacy |
WO2007022524A2 (en) | 2005-08-19 | 2007-02-22 | Neuronetrix, Inc. | Controller for neuromuscular testing |
US20060058854A1 (en) * | 2004-09-14 | 2006-03-16 | Scimed Life Systems, Inc. | Method for stimulating neural tissue in response to a sensed physiological event |
US7353065B2 (en) * | 2004-09-14 | 2008-04-01 | Neuropace, Inc. | Responsive therapy for psychiatric disorders |
US7857746B2 (en) * | 2004-10-29 | 2010-12-28 | Nueronetics, Inc. | System and method to reduce discomfort using nerve stimulation |
US7565200B2 (en) | 2004-11-12 | 2009-07-21 | Advanced Neuromodulation Systems, Inc. | Systems and methods for selecting stimulation sites and applying treatment, including treatment of symptoms of Parkinson's disease, other movement disorders, and/or drug side effects |
US20060111743A1 (en) * | 2004-11-19 | 2006-05-25 | Gurney Harry C Jr | Method for arresting seizure activity |
US20060129056A1 (en) * | 2004-12-10 | 2006-06-15 | Washington University | Electrocorticography telemitter |
US7819812B2 (en) | 2004-12-15 | 2010-10-26 | Neuropace, Inc. | Modulation and analysis of cerebral perfusion in epilepsy and other neurological disorders |
US7783359B2 (en) * | 2005-01-05 | 2010-08-24 | Boston Scientific Neuromodulation Corporation | Devices and methods using an implantable pulse generator for brain stimulation |
US7809446B2 (en) | 2005-01-05 | 2010-10-05 | Boston Scientific Neuromodulation Corporation | Devices and methods for brain stimulation |
US8088058B2 (en) * | 2005-01-20 | 2012-01-03 | Neuronetics, Inc. | Articulating arm |
US8600521B2 (en) * | 2005-01-27 | 2013-12-03 | Cyberonics, Inc. | Implantable medical device having multiple electrode/sensor capability and stimulation based on sensed intrinsic activity |
US8565867B2 (en) | 2005-01-28 | 2013-10-22 | Cyberonics, Inc. | Changeable electrode polarity stimulation by an implantable medical device |
US9314633B2 (en) | 2008-01-25 | 2016-04-19 | Cyberonics, Inc. | Contingent cardio-protection for epilepsy patients |
EP1863562A4 (en) * | 2005-03-01 | 2009-10-21 | Northstar Neuroscience Inc | Method of treating depression, mood disorders and anxiety disorders using neuromodulation |
US20060199159A1 (en) * | 2005-03-01 | 2006-09-07 | Neuronetics, Inc. | Head phantom for simulating the patient response to magnetic stimulation |
WO2006094072A2 (en) * | 2005-03-01 | 2006-09-08 | Functional Neuroscience Inc. | Method of treating cognitive disorders using neuromodulation |
US7627383B2 (en) | 2005-03-15 | 2009-12-01 | Boston Scientific Neuromodulation Corporation | Implantable stimulator |
US20110077579A1 (en) * | 2005-03-24 | 2011-03-31 | Harrison William V | Cochlear implant with localized fluid transport |
US7493161B2 (en) | 2005-05-10 | 2009-02-17 | Cardiac Pacemakers, Inc. | System and method to deliver therapy in presence of another therapy |
US7801602B2 (en) * | 2005-04-08 | 2010-09-21 | Boston Scientific Neuromodulation Corporation | Controlling stimulation parameters of implanted tissue stimulators |
US7396326B2 (en) * | 2005-05-17 | 2008-07-08 | Neuronetics, Inc. | Ferrofluidic cooling and acoustical noise reduction in magnetic stimulators |
US7801600B1 (en) | 2005-05-26 | 2010-09-21 | Boston Scientific Neuromodulation Corporation | Controlling charge flow in the electrical stimulation of tissue |
US10052497B2 (en) | 2005-07-22 | 2018-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
US8926959B2 (en) | 2005-07-22 | 2015-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
US20090093403A1 (en) | 2007-03-01 | 2009-04-09 | Feng Zhang | Systems, methods and compositions for optical stimulation of target cells |
US9278159B2 (en) * | 2005-07-22 | 2016-03-08 | The Board Of Trustees Of The Leland Stanford Junior University | Light-activated cation channel and uses thereof |
US9238150B2 (en) | 2005-07-22 | 2016-01-19 | The Board Of Trustees Of The Leland Stanford Junior University | Optical tissue interface method and apparatus for stimulating cells |
US9274099B2 (en) | 2005-07-22 | 2016-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Screening test drugs to identify their effects on cell membrane voltage-gated ion channel |
US7824324B2 (en) * | 2005-07-27 | 2010-11-02 | Neuronetics, Inc. | Magnetic core for medical procedures |
US7532935B2 (en) * | 2005-07-29 | 2009-05-12 | Cyberonics, Inc. | Selective neurostimulation for treating mood disorders |
US20070027499A1 (en) * | 2005-07-29 | 2007-02-01 | Cyberonics, Inc. | Neurostimulation device for treating mood disorders |
US7499752B2 (en) | 2005-07-29 | 2009-03-03 | Cyberonics, Inc. | Selective nerve stimulation for the treatment of eating disorders |
US20070055320A1 (en) * | 2005-09-07 | 2007-03-08 | Northstar Neuroscience, Inc. | Methods for treating temporal lobe epilepsy, associated neurological disorders, and other patient functions |
US8929991B2 (en) | 2005-10-19 | 2015-01-06 | Advanced Neuromodulation Systems, Inc. | Methods for establishing parameters for neural stimulation, including via performance of working memory tasks, and associated kits |
US20070088404A1 (en) * | 2005-10-19 | 2007-04-19 | Allen Wyler | Methods and systems for improving neural functioning, including cognitive functioning and neglect disorders |
US7729773B2 (en) | 2005-10-19 | 2010-06-01 | Advanced Neuromodualation Systems, Inc. | Neural stimulation and optical monitoring systems and methods |
US7856264B2 (en) * | 2005-10-19 | 2010-12-21 | Advanced Neuromodulation Systems, Inc. | Systems and methods for patient interactive neural stimulation and/or chemical substance delivery |
US7957796B2 (en) | 2005-10-28 | 2011-06-07 | Cyberonics, Inc. | Using physiological sensor data with an implantable medical device |
US7729758B2 (en) * | 2005-11-30 | 2010-06-01 | Boston Scientific Neuromodulation Corporation | Magnetically coupled microstimulators |
US7570999B2 (en) | 2005-12-20 | 2009-08-04 | Cardiac Pacemakers, Inc. | Implantable device for treating epilepsy and cardiac rhythm disorders |
US8868172B2 (en) | 2005-12-28 | 2014-10-21 | Cyberonics, Inc. | Methods and systems for recommending an appropriate action to a patient for managing epilepsy and other neurological disorders |
US8725243B2 (en) | 2005-12-28 | 2014-05-13 | Cyberonics, Inc. | Methods and systems for recommending an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders |
US7657310B2 (en) | 2006-01-26 | 2010-02-02 | Cyberonics, Inc. | Treatment of reproductive endocrine disorders by vagus nerve stimulation |
US7801601B2 (en) | 2006-01-27 | 2010-09-21 | Cyberonics, Inc. | Controlling neuromodulation using stimulus modalities |
DE102006008501B3 (en) * | 2006-02-23 | 2007-10-25 | Albert-Ludwigs-Universität Freiburg | Probe and method for data transfer between a brain and a data processing device |
US7894905B2 (en) * | 2006-03-13 | 2011-02-22 | Neuropace, Inc. | Implantable system enabling responsive therapy for pain |
US8744587B2 (en) | 2006-03-24 | 2014-06-03 | Medtronic, Inc. | Collecting gait information for evaluation and control of therapy |
BRPI0709844A2 (en) | 2006-03-29 | 2011-07-26 | Catholic Healthcare West | Cranial nerve micrograde electrical stimulation for the treatment of medical conditions |
US8926676B2 (en) * | 2006-04-11 | 2015-01-06 | Advanced Neuromodulation Systems, Inc. | Systems and methods for applying signals, including contralesional signals, to neural populations |
US20120035438A1 (en) | 2006-04-12 | 2012-02-09 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Path selection by a lumen traveling device in a body tub tree based on previous path |
US9220917B2 (en) | 2006-04-12 | 2015-12-29 | The Invention Science Fund I, Llc | Systems for autofluorescent imaging and target ablation |
US9084901B2 (en) | 2006-04-28 | 2015-07-21 | Medtronic, Inc. | Cranial implant |
US8326431B2 (en) * | 2006-04-28 | 2012-12-04 | Medtronic, Inc. | Implantable medical device for the concurrent treatment of a plurality of neurological disorders and method therefore |
US7869885B2 (en) | 2006-04-28 | 2011-01-11 | Cyberonics, Inc | Threshold optimization for tissue stimulation therapy |
US9480846B2 (en) | 2006-05-17 | 2016-11-01 | Medtronic Urinary Solutions, Inc. | Systems and methods for patient control of stimulation systems |
US7803148B2 (en) | 2006-06-09 | 2010-09-28 | Neurosystec Corporation | Flow-induced delivery from a drug mass |
EP2034885A4 (en) | 2006-06-23 | 2010-12-01 | Neurovista Corp | Minimally invasive monitoring systems and methods |
ES2664415T3 (en) | 2006-07-05 | 2018-04-19 | Precisis Ag | System for the treatment of neurological disorders by electrical stimulation |
US20080103548A1 (en) * | 2006-08-02 | 2008-05-01 | Northstar Neuroscience, Inc. | Methods for treating neurological disorders, including neuropsychiatric and neuropsychological disorders, and associated systems |
US7869867B2 (en) | 2006-10-27 | 2011-01-11 | Cyberonics, Inc. | Implantable neurostimulator with refractory stimulation |
US8280514B2 (en) | 2006-10-31 | 2012-10-02 | Advanced Neuromodulation Systems, Inc. | Identifying areas of the brain by examining the neuronal signals |
US8295934B2 (en) | 2006-11-14 | 2012-10-23 | Neurovista Corporation | Systems and methods of reducing artifact in neurological stimulation systems |
WO2008086470A1 (en) | 2007-01-10 | 2008-07-17 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
US9898656B2 (en) | 2007-01-25 | 2018-02-20 | Cyberonics, Inc. | Systems and methods for identifying a contra-ictal condition in a subject |
WO2008092133A2 (en) | 2007-01-25 | 2008-07-31 | Neurovista Corporation | Methods and systems for measuring a subject's susceptibility to a seizure |
US8401609B2 (en) * | 2007-02-14 | 2013-03-19 | The Board Of Trustees Of The Leland Stanford Junior University | System, method and applications involving identification of biological circuits such as neurological characteristics |
US8128549B2 (en) * | 2007-02-20 | 2012-03-06 | Neuronetics, Inc. | Capacitor failure detection |
US8036736B2 (en) | 2007-03-21 | 2011-10-11 | Neuro Vista Corporation | Implantable systems and methods for identifying a contra-ictal condition in a subject |
US7974701B2 (en) | 2007-04-27 | 2011-07-05 | Cyberonics, Inc. | Dosing limitation for an implantable medical device |
US7801618B2 (en) * | 2007-06-22 | 2010-09-21 | Neuropace, Inc. | Auto adjusting system for brain tissue stimulator |
US8694105B2 (en) * | 2007-07-10 | 2014-04-08 | Sapiens Steering Brain Stimulation B.V. | Neurostimulation system having a controller for controlling the supply of electrical pulses |
US9788744B2 (en) | 2007-07-27 | 2017-10-17 | Cyberonics, Inc. | Systems for monitoring brain activity and patient advisory device |
US7877136B1 (en) | 2007-09-28 | 2011-01-25 | Boston Scientific Neuromodulation Corporation | Enhancement of neural signal transmission through damaged neural tissue via hyperpolarizing electrical stimulation current |
US7860569B2 (en) | 2007-10-18 | 2010-12-28 | Brainsgate, Ltd. | Long-term SPG stimulation therapy for prevention of vascular dementia |
US10434327B2 (en) | 2007-10-31 | 2019-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Implantable optical stimulators |
US10035027B2 (en) * | 2007-10-31 | 2018-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Device and method for ultrasonic neuromodulation via stereotactic frame based technique |
US9248280B2 (en) * | 2007-11-02 | 2016-02-02 | Boston Scientific Neuromodulation Corporation | Closed-loop feedback for steering stimulation energy within tissue |
US20090118804A1 (en) * | 2007-11-05 | 2009-05-07 | Advanced Bionics Corporation | Method of mounting minimally invasive plug electrodes within cranium of patient |
US8538537B2 (en) * | 2007-12-07 | 2013-09-17 | Advanced Neuromodulations Systems, Inc. | Systems and methods for providing targeted neural stimulation therapy to address neurological disorders, including neuropyschiatric and neuropyschological disorders |
US20090171168A1 (en) | 2007-12-28 | 2009-07-02 | Leyde Kent W | Systems and Method for Recording Clinical Manifestations of a Seizure |
US9259591B2 (en) | 2007-12-28 | 2016-02-16 | Cyberonics, Inc. | Housing for an implantable medical device |
US8571643B2 (en) | 2010-09-16 | 2013-10-29 | Flint Hills Scientific, Llc | Detecting or validating a detection of a state change from a template of heart rate derivative shape or heart beat wave complex |
US8382667B2 (en) | 2010-10-01 | 2013-02-26 | Flint Hills Scientific, Llc | Detecting, quantifying, and/or classifying seizures using multimodal data |
US8337404B2 (en) | 2010-10-01 | 2012-12-25 | Flint Hills Scientific, Llc | Detecting, quantifying, and/or classifying seizures using multimodal data |
US9884200B2 (en) * | 2008-03-10 | 2018-02-06 | Neuronetics, Inc. | Apparatus for coil positioning for TMS studies |
US9149599B2 (en) * | 2008-04-09 | 2015-10-06 | Lotus Magnus, Llc | Brain stimulation systems and methods |
CA2722278C (en) | 2008-04-23 | 2020-03-31 | Feng Zhang | Systems, methods and compositions for optical stimulation of target cells |
US8204603B2 (en) * | 2008-04-25 | 2012-06-19 | Cyberonics, Inc. | Blocking exogenous action potentials by an implantable medical device |
US8315703B2 (en) * | 2008-04-30 | 2012-11-20 | Advanced Neuromodulation Systems, Inc. | Methods for targeting deep brain sites to treat mood and/or anxiety disorders |
MX2010012986A (en) * | 2008-05-29 | 2011-05-25 | Univ Leland Stanford Junior | Cell line, system and method for optical control of secondary messengers. |
CA2728238C (en) | 2008-06-17 | 2019-03-12 | M. Bret Schneider | Methods, systems and devices for optical stimulation of target cells using an optical transmission element |
BRPI0915583A2 (en) * | 2008-06-17 | 2016-01-26 | Univ Leland Stanford Junior | apparatus and methods for controlling cell development |
WO2010006049A1 (en) | 2008-07-08 | 2010-01-14 | The Board Of Trustees Of The Leland Stanford Junior University | Materials and approaches for optical stimulation of the peripheral nervous system |
US8262714B2 (en) * | 2008-08-05 | 2012-09-11 | Advanced Neuromodulation Systems, Inc. | Techniques for selecting signal delivery sites and other parameters for treating depression and other neurological disorders, and associated systems and methods |
ES2462759T3 (en) | 2008-10-01 | 2014-05-26 | Sherwin Hua | System for pedicle screw stabilization guided by column vertebrae wire |
US8457747B2 (en) | 2008-10-20 | 2013-06-04 | Cyberonics, Inc. | Neurostimulation with signal duration determined by a cardiac cycle |
US8417344B2 (en) | 2008-10-24 | 2013-04-09 | Cyberonics, Inc. | Dynamic cranial nerve stimulation based on brain state determination from cardiac data |
US9393432B2 (en) | 2008-10-31 | 2016-07-19 | Medtronic, Inc. | Non-hermetic direct current interconnect |
NZ602416A (en) | 2008-11-14 | 2014-08-29 | Univ Leland Stanford Junior | Optically-based stimulation of target cells and modifications thereto |
US8849390B2 (en) | 2008-12-29 | 2014-09-30 | Cyberonics, Inc. | Processing for multi-channel signals |
US8588933B2 (en) | 2009-01-09 | 2013-11-19 | Cyberonics, Inc. | Medical lead termination sleeve for implantable medical devices |
US20100191304A1 (en) | 2009-01-23 | 2010-07-29 | Scott Timothy L | Implantable Medical Device for Providing Chronic Condition Therapy and Acute Condition Therapy Using Vagus Nerve Stimulation |
US9095303B2 (en) | 2009-03-23 | 2015-08-04 | Flint Hills Scientific, Llc | System and apparatus for early detection, prevention, containment or abatement of spread abnormal brain activity |
KR20120026505A (en) * | 2009-04-24 | 2012-03-19 | 케어퓨전 2200, 아이엔씨 | Cortical stimulator method and apparatus |
US8239028B2 (en) | 2009-04-24 | 2012-08-07 | Cyberonics, Inc. | Use of cardiac parameters in methods and systems for treating a chronic medical condition |
US8827912B2 (en) | 2009-04-24 | 2014-09-09 | Cyberonics, Inc. | Methods and systems for detecting epileptic events using NNXX, optionally with nonlinear analysis parameters |
US8786624B2 (en) | 2009-06-02 | 2014-07-22 | Cyberonics, Inc. | Processing for multi-channel signals |
US8295944B2 (en) | 2009-11-30 | 2012-10-23 | Boston Scientific Neuromodulation Corporation | Electrode array with electrodes having cutout portions and methods of making the same |
US8391985B2 (en) * | 2009-11-30 | 2013-03-05 | Boston Scientific Neuromodulation Corporation | Electrode array having concentric windowed cylinder electrodes and methods of making the same |
KR20130004253A (en) | 2009-12-21 | 2013-01-09 | 셔윈 화 | Insertion of medical devices through non-orthogonal and orthogonal trajectories within the cranium and methods of using |
US8352039B2 (en) * | 2010-01-08 | 2013-01-08 | Medtronic, Inc. | Programming therapy delivered by implantable medical device |
WO2011085232A1 (en) * | 2010-01-08 | 2011-07-14 | Medtronic, Inc. | Presentation of information associated with medical device therapy |
US9643019B2 (en) | 2010-02-12 | 2017-05-09 | Cyberonics, Inc. | Neurological monitoring and alerts |
SG183899A1 (en) | 2010-03-17 | 2012-10-30 | Univ Leland Stanford Junior | Light-sensitive ion-passing molecules |
US8831732B2 (en) | 2010-04-29 | 2014-09-09 | Cyberonics, Inc. | Method, apparatus and system for validating and quantifying cardiac beat data quality |
US8562536B2 (en) | 2010-04-29 | 2013-10-22 | Flint Hills Scientific, Llc | Algorithm for detecting a seizure from cardiac data |
US8649871B2 (en) | 2010-04-29 | 2014-02-11 | Cyberonics, Inc. | Validity test adaptive constraint modification for cardiac data used for detection of state changes |
US8679009B2 (en) | 2010-06-15 | 2014-03-25 | Flint Hills Scientific, Llc | Systems approach to comorbidity assessment |
US8641646B2 (en) | 2010-07-30 | 2014-02-04 | Cyberonics, Inc. | Seizure detection using coordinate data |
US8684921B2 (en) | 2010-10-01 | 2014-04-01 | Flint Hills Scientific Llc | Detecting, assessing and managing epilepsy using a multi-variate, metric-based classification analysis |
EP3225108A1 (en) | 2010-11-05 | 2017-10-04 | The Board of Trustees of The Leland Stanford Junior University | Optogenetic control of reward-related behaviors |
ES2684307T3 (en) | 2010-11-05 | 2018-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Stabilized opsin-type proteins of staggered function and methods of use thereof |
US10086012B2 (en) | 2010-11-05 | 2018-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Control and characterization of memory function |
EP3486253A1 (en) | 2010-11-05 | 2019-05-22 | The Board of Trustees of The Leland Stanford Junior University | Light-activated chimeric opsins and methods of using the same |
CN106422081B (en) | 2010-11-05 | 2019-06-21 | 斯坦福大学托管董事会 | The upper conversion of light for light genetic method |
CN106106368A (en) | 2010-11-05 | 2016-11-16 | 斯坦福大学托管董事会 | Optically-controlledCNS CNS dysfunction |
US8696722B2 (en) | 2010-11-22 | 2014-04-15 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic magnetic resonance imaging |
US9504390B2 (en) | 2011-03-04 | 2016-11-29 | Globalfoundries Inc. | Detecting, assessing and managing a risk of death in epilepsy |
US8725239B2 (en) | 2011-04-25 | 2014-05-13 | Cyberonics, Inc. | Identifying seizures using heart rate decrease |
US9402550B2 (en) | 2011-04-29 | 2016-08-02 | Cybertronics, Inc. | Dynamic heart rate threshold for neurological event detection |
US8663202B2 (en) * | 2011-05-20 | 2014-03-04 | Advastim, Inc. | Wireless remote neurostimulator |
US9278495B2 (en) | 2011-08-03 | 2016-03-08 | Milliken & Company | Rubber reinforced article with high modulus, rectangular cross-section fibers |
US9267566B2 (en) | 2012-01-17 | 2016-02-23 | Milliken & Company | Polyester/nylon 6 fibers for rubber reinforcement |
US10206591B2 (en) | 2011-10-14 | 2019-02-19 | Flint Hills Scientific, Llc | Seizure detection methods, apparatus, and systems using an autoregression algorithm |
CA2859364C (en) | 2011-12-16 | 2019-05-07 | The Board Of Trustees Of The Leland Stanford Junior University | Opsin polypeptides and methods of use thereof |
DE102012002437B4 (en) | 2012-02-08 | 2014-08-21 | Forschungszentrum Jülich GmbH | Device for calibrating an invasive, electrical and desynchronizing neurostimulation |
CA2865296A1 (en) | 2012-02-21 | 2013-08-29 | Karl A. DEISSEROTH | Compositions and methods for treating neurogenic disorders of the pelvic floor |
WO2013158709A1 (en) * | 2012-04-17 | 2013-10-24 | Flint Hills Scientific, Llc | System and apparatus for early detection, prevention, containment or abatement of spread abnormal brain activity |
US8918176B2 (en) * | 2012-04-23 | 2014-12-23 | Medtronic, Inc. | Assessing cognitive disorders based on non-motor epileptiform bioelectrical brain activity |
US10448839B2 (en) | 2012-04-23 | 2019-10-22 | Livanova Usa, Inc. | Methods, systems and apparatuses for detecting increased risk of sudden death |
DE102012107838A1 (en) | 2012-08-24 | 2014-02-27 | Albert-Ludwigs-Universität Freiburg | Sensor device for detecting bioelectric signals |
US11662818B2 (en) | 2012-08-31 | 2023-05-30 | Blue Goji Llc. | System and method for evaluation, detection, conditioning, and treatment of neurological functioning and conditions |
US11465013B2 (en) * | 2012-08-31 | 2022-10-11 | Blue Goji Llc | System and method for targeted neurological therapy using brainwave entrainment |
US11791026B2 (en) * | 2012-08-31 | 2023-10-17 | Blue Goji Llc | Cloud-based healthcare diagnostics and treatment platform |
US20140066949A1 (en) * | 2012-09-06 | 2014-03-06 | Covidien Lp | Neurological Treatment System |
US8849408B1 (en) | 2013-01-04 | 2014-09-30 | University Of Central Florida Research Foundation, Inc. | Methods for electronic directionality of deep-brain stimulation |
US10220211B2 (en) | 2013-01-22 | 2019-03-05 | Livanova Usa, Inc. | Methods and systems to diagnose depression |
US9427593B2 (en) | 2013-03-12 | 2016-08-30 | Neuropace, Inc. | Measuring current during delivery of voltage regulated stimulation to a patient |
US9636380B2 (en) | 2013-03-15 | 2017-05-02 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic control of inputs to the ventral tegmental area |
EP2968997B1 (en) | 2013-03-15 | 2019-06-26 | The Board of Trustees of the Leland Stanford Junior University | Optogenetic control of behavioral state |
WO2014179331A2 (en) | 2013-04-29 | 2014-11-06 | The Board Of Trustees Of The Leland Stanford Junior University | Devices, systems and methods for optogenetic modulation of action potentials in target cells |
US9839777B2 (en) | 2013-08-14 | 2017-12-12 | Syntilla Medical LLC | Implantable neurostimulation lead for head pain |
US9427566B2 (en) | 2013-08-14 | 2016-08-30 | Syntilla Medical LLC | Implantable neurostimulation lead for head pain |
WO2015023782A1 (en) | 2013-08-14 | 2015-02-19 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for controlling pain |
US9042991B2 (en) | 2013-08-14 | 2015-05-26 | Syntilla Medical LLC | Implantable head mounted neurostimulation system for head pain |
US9498635B2 (en) | 2013-10-16 | 2016-11-22 | Syntilla Medical LLC | Implantable head located radiofrequency coupled neurostimulation system for head pain |
US10960215B2 (en) | 2013-10-23 | 2021-03-30 | Nuxcel, Inc. | Low profile head-located neurostimulator and method of fabrication |
US10258805B2 (en) | 2013-10-23 | 2019-04-16 | Syntilla Medical, Llc | Surgical method for implantable head mounted neurostimulation system for head pain |
EP2878335B1 (en) | 2013-11-10 | 2018-01-03 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
CN104622468B (en) * | 2013-11-14 | 2020-04-07 | 先健科技(深圳)有限公司 | Deep brain stimulation system with external prediction function |
WO2016053375A1 (en) | 2014-10-01 | 2016-04-07 | James Phillips | System and method for transcranial current loop brain stimulation |
US20170265764A1 (en) * | 2014-11-24 | 2017-09-21 | Ivan Osorio | Subcortical (thalamic) automated seizure detection for contingent therapy delivery systems and methods |
EP3093043B1 (en) | 2015-05-13 | 2018-11-14 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
US10456073B2 (en) * | 2015-06-09 | 2019-10-29 | The Governing Council Of The University Of Toronto | System, method and apparatus for rapid brief feedback intracerebral stimulation based on real-time desynchronization |
CA2988789A1 (en) | 2015-06-09 | 2016-12-15 | The Governing Council Of The University Of Toronto | Systems, methods and apparatuses for in situ electrochemical imaging |
US10568516B2 (en) | 2015-06-22 | 2020-02-25 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and devices for imaging and/or optogenetic control of light-responsive neurons |
EP3360232A4 (en) | 2015-10-07 | 2019-05-22 | The Governing Council Of The University Of Toronto | Wireless power and data transmission system for wearable and implantable devices |
US10252056B2 (en) | 2015-11-18 | 2019-04-09 | David J. Mogul | Method and apparatus for preventing or terminating epileptic seizures |
US11801381B2 (en) * | 2015-12-09 | 2023-10-31 | Lawrence Livermore National Security, Llc | Implantable neuromodulation system for closed-loop stimulation and recording simultaneously at multiple brain sets |
US9717917B2 (en) | 2016-01-06 | 2017-08-01 | Syntilla Medical LLC | Charging system incorporating independent charging and communication with multiple implanted devices |
CA3029898A1 (en) | 2016-07-20 | 2018-01-25 | The Governing Council Of The University Of Toronto | Neurostimulator and method for delivering a stimulation in response to a predicted or detected neurophysiological condition |
WO2018027259A1 (en) | 2016-08-08 | 2018-02-15 | Bionics Institute | Systems and methods for monitoring neural activity |
WO2018072894A1 (en) | 2016-10-19 | 2018-04-26 | Precisis Ag | Methods and devices for the electrical stimulation of brain tissue via electrodes within cranial bone |
US11294165B2 (en) | 2017-03-30 | 2022-04-05 | The Board Of Trustees Of The Leland Stanford Junior University | Modular, electro-optical device for increasing the imaging field of view using time-sequential capture |
JP7144450B2 (en) | 2017-05-22 | 2022-09-29 | ディープ・ブレイン・スティムレーション・テクノロジーズ・ピーティーワイ・リミテッド | Systems and methods for monitoring neural activity |
US11172868B2 (en) * | 2017-07-21 | 2021-11-16 | Yi Zheng | Screening of malignant glioma, brain tumors, and brain injuries using disturbance coefficient, differential impedances, and artificial neural network |
US11596795B2 (en) | 2017-07-31 | 2023-03-07 | Medtronic, Inc. | Therapeutic electrical stimulation therapy for patient gait freeze |
US11172857B2 (en) | 2018-07-11 | 2021-11-16 | The Governing Council Of The University Of Toronto | System, system architecture, and method for neural cross-frequency coupling analysis |
US11160580B2 (en) | 2019-04-24 | 2021-11-02 | Spine23 Inc. | Systems and methods for pedicle screw stabilization of spinal vertebrae |
CN111134665B (en) * | 2019-12-30 | 2024-01-30 | 龙岩学院 | Wearable epileptic monitoring facilities |
WO2021168467A2 (en) * | 2020-02-18 | 2021-08-26 | Blue Goji Llc | A system and method for evaluation, detection, conditioning, and treatment of neurological functioning and conditions |
CN116648284B (en) * | 2020-12-18 | 2024-02-20 | 大脑连接有限公司 | Implantable neurophysiologic device |
WO2022256385A1 (en) * | 2021-06-01 | 2022-12-08 | EPIC Neuro, Inc. | Subcutaneous transcranial cortical electrotherapy stimulation method and device |
CN116251295A (en) * | 2023-03-09 | 2023-06-13 | 北京工业大学 | Focal epileptic electric guidance-nerve electric regulation and control system and method |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3850161A (en) * | 1973-04-09 | 1974-11-26 | S Liss | Method and apparatus for monitoring and counteracting excess brain electrical energy to prevent epileptic seizures and the like |
US6016449A (en) * | 1997-10-27 | 2000-01-18 | Neuropace, Inc. | System for treatment of neurological disorders |
US6227203B1 (en) * | 1998-02-12 | 2001-05-08 | Medtronic, Inc. | Techniques for controlling abnormal involuntary movements by brain stimulation and drug infusion |
US6230049B1 (en) * | 1999-08-13 | 2001-05-08 | Neuro Pace, Inc. | Integrated system for EEG monitoring and electrical stimulation with a multiplicity of electrodes |
US6272370B1 (en) * | 1998-08-07 | 2001-08-07 | The Regents Of University Of Minnesota | MR-visible medical device for neurological interventions using nonlinear magnetic stereotaxis and a method imaging |
US6597954B1 (en) * | 1997-10-27 | 2003-07-22 | Neuropace, Inc. | System and method for controlling epileptic seizures with spatially separated detection and stimulation electrodes |
US6671555B2 (en) * | 2001-04-27 | 2003-12-30 | Medtronic, Inc. | Closed loop neuromodulation for suppression of epileptic activity |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5975085A (en) * | 1997-05-01 | 1999-11-02 | Medtronic, Inc. | Method of treating schizophrenia by brain stimulation and drug infusion |
-
2000
- 2000-11-28 US US09/724,805 patent/US6597954B1/en not_active Expired - Lifetime
-
2003
- 2003-07-22 US US10/625,829 patent/US20040153129A1/en not_active Abandoned
-
2006
- 2006-05-16 US US11/436,189 patent/US20060224216A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3850161A (en) * | 1973-04-09 | 1974-11-26 | S Liss | Method and apparatus for monitoring and counteracting excess brain electrical energy to prevent epileptic seizures and the like |
US6016449A (en) * | 1997-10-27 | 2000-01-18 | Neuropace, Inc. | System for treatment of neurological disorders |
US6597954B1 (en) * | 1997-10-27 | 2003-07-22 | Neuropace, Inc. | System and method for controlling epileptic seizures with spatially separated detection and stimulation electrodes |
US6227203B1 (en) * | 1998-02-12 | 2001-05-08 | Medtronic, Inc. | Techniques for controlling abnormal involuntary movements by brain stimulation and drug infusion |
US6272370B1 (en) * | 1998-08-07 | 2001-08-07 | The Regents Of University Of Minnesota | MR-visible medical device for neurological interventions using nonlinear magnetic stereotaxis and a method imaging |
US6230049B1 (en) * | 1999-08-13 | 2001-05-08 | Neuro Pace, Inc. | Integrated system for EEG monitoring and electrical stimulation with a multiplicity of electrodes |
US6671555B2 (en) * | 2001-04-27 | 2003-12-30 | Medtronic, Inc. | Closed loop neuromodulation for suppression of epileptic activity |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070073150A1 (en) * | 2005-09-29 | 2007-03-29 | University Of Chicago | Surface acoustic wave probe implant for predicting epileptic seizures |
US8165682B2 (en) * | 2005-09-29 | 2012-04-24 | Uchicago Argonne, Llc | Surface acoustic wave probe implant for predicting epileptic seizures |
US20110021885A1 (en) * | 2007-05-03 | 2011-01-27 | Cornell Research Foundation, Inc. | Subdural electro-optical sensor |
US9521955B2 (en) | 2007-05-03 | 2016-12-20 | Cornell Research Foundtion, Inc. | Subdural electro-optical sensor |
US20100023100A1 (en) * | 2008-07-24 | 2010-01-28 | Boston Scientific Neoromodulation Corporation | Cam lock burr hole plug for securing stimulation lead |
US20100023020A1 (en) * | 2008-07-24 | 2010-01-28 | Boston Scientific Neuromodulation Corporation | Cam lock burr hole plug for securing retainer/plug base |
US8043304B2 (en) | 2008-07-24 | 2011-10-25 | Boston Scientific Neuromodulation Corporation | Cam lock burr hole plug for securing retainer/plug base |
US8425534B2 (en) | 2008-07-24 | 2013-04-23 | Boston Scientific Neuromodulation Corporation | Cam lock burr hole plug for securing stimulation lead |
US8764767B2 (en) | 2008-07-24 | 2014-07-01 | Boston Scientific Neuromodulation Corporation | Cam lock burr hole plug for securing stimulation lead |
US20100228075A1 (en) * | 2009-03-06 | 2010-09-09 | Neuralieve | Method and Apparatus to Record and Analyze TMS Treatments and Results |
WO2010102221A1 (en) | 2009-03-06 | 2010-09-10 | Neuralieve | Method and apparatus to record and analyze tms treatments and results |
US9492680B2 (en) | 2009-03-06 | 2016-11-15 | Neuralieve | Method and apparatus to record and analyze TMS treatments and results |
US10232169B2 (en) | 2015-07-23 | 2019-03-19 | Boston Scientific Neuromodulation Corporation | Burr hole plugs for electrical stimulation systems and methods of making and using |
US11723579B2 (en) | 2017-09-19 | 2023-08-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
US11103716B2 (en) | 2017-11-13 | 2021-08-31 | Boston Scientific Neuromodulation Corporation | Systems and methods for making and using a low-profile control module for an electrical stimulation system |
US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
US11273283B2 (en) | 2017-12-31 | 2022-03-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
US11318277B2 (en) | 2017-12-31 | 2022-05-03 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
US11478603B2 (en) | 2017-12-31 | 2022-10-25 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
US11497914B2 (en) | 2018-01-16 | 2022-11-15 | Boston Scientific Neuromodulation Corporation | Systems and methods for making and using an electrical stimulation system with a case-neutral battery |
US11058870B2 (en) | 2018-03-09 | 2021-07-13 | Boston Scientific Neuromodulation Corporation | Burr hole plugs for electrical stimulation systems and methods of making and using |
US11013913B2 (en) | 2018-03-16 | 2021-05-25 | Boston Scientific Neuromodulation Corporation | Kits and methods for securing a burr hole plugs for stimulation systems |
US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
US11452839B2 (en) | 2018-09-14 | 2022-09-27 | Neuroenhancement Lab, LLC | System and method of improving sleep |
Also Published As
Publication number | Publication date |
---|---|
US6597954B1 (en) | 2003-07-22 |
US20040153129A1 (en) | 2004-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6597954B1 (en) | System and method for controlling epileptic seizures with spatially separated detection and stimulation electrodes | |
EP1335668B1 (en) | Detecting neurological dysfunction | |
US6529774B1 (en) | Extradural leads, neurostimulator assemblies, and processes of using them for somatosensory and brain stimulation | |
US6466822B1 (en) | Multimodal neurostimulator and process of using it | |
US8190248B2 (en) | Medical devices for the detection, prevention and/or treatment of neurological disorders, and methods related thereto | |
US8326417B2 (en) | Neurostimulator involving stimulation strategies and process for using it | |
US6959215B2 (en) | Methods for treating essential tremor | |
US6430443B1 (en) | Method and apparatus for treating auditory hallucinations | |
US8249712B2 (en) | Treatment and warning of recurring therapy and other events using an implantable device | |
US20160317814A1 (en) | Extracranial implantable devices, systems and methods for the treatment of neurological disorders | |
US20080125830A1 (en) | Responsive Therapy for Psychiatric Disorders | |
EP1809369A2 (en) | Medical devices for the detection, prevention and/or treatment of neurological disorders, and methods related thereto | |
US20140081348A1 (en) | Low-frequency stimulation systems and methods | |
US20150290460A1 (en) | Methods for Treating Mild Cognitive Impairment and Alzheimer's Disease | |
US20200179696A1 (en) | Suppressing seizures with low frequency stimulation of the corpus callosum | |
Velasco et al. | Interfering with the genesis and propagation of epileptic seizures by neuromodulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NEUROPACE, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PLESS, BENJAMIN D.;FISCHELL, ROBERT E.;FISCHELL, DAVID R.;REEL/FRAME:017814/0939;SIGNING DATES FROM 20010607 TO 20010627 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |